- 1 Egg-derived anti-SARS-CoV-2 immunoglobulin Y (IgY)
- with broad variant activity as intranasal prophylaxis against
- 3 COVID-19: preclinical studies and randomized controlled
- 4 phase 1 clinical trial
- 6 **Short Title:** Intranasal egg-derived anti-SARS-CoV-2 IgY antibodies for passive immunization
- 7 **Authors:** Lyn R. Frumkin¹¶, Michaela Lucas²¶, Curtis L. Scribner³, Nastassja Ortega-Heinly⁴,
- ⁸ Jayden Rogers⁵, Gang Yin⁶, Trevor J Hallam⁶, Alice Yam⁶, Kristin Bedard⁶, Rebecca Begley¹,
- 9 Courtney A. Cohen^{7,8}, Catherine V. Badger⁷, Shawn A. Abbasi⁷, John M. Dye⁷, Brian
- McMillan⁹, Michael Wallach¹⁰, Traci L. Bricker¹¹, Astha Joshi¹¹, Adrianus C.M. Boon¹¹, Suman
- Pokhrel¹², Benjamin R. Kraemer¹², Lucia Lee¹², Stephen Kargotich¹³, Mahima Agogiya¹, Tom St.
- 12 John¹⁴, Daria Mochly-Rosen^{1,12,13*}
- 14 **Affiliations:**

5

- ¹ SPARK at Stanford, Stanford University, School of Medicine, Stanford, California, United
- 16 States of America
- ² Faculty of Health and Medical Sciences Internal Medicine, The University of Western
- 18 Australia, Perth, Western Australia, Australia
- ³ Independent Regulatory Consultant, Oakland, California, United States of America
- ⁴ Avian Vaccine Services, Charles River Laboratories, Storrs, Connecticut, United States of
- 21 America

- ⁵ Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
- ⁶ Sutro Biopharma Inc., South San Francisco, California, United States of America
- ⁷ United States Army Medical Research Institute of Infectious Diseases, Virology Division,
- 25 Frederick, Maryland, United States of America
- ⁸ The Geneva Foundation, Tacoma, Washington, United States of America
- ⁹ Bravado Pharmaceuticals, Lutz, Florida, United States of America
- ¹⁰ University of Technology Sydney, Sydney, New South Wales, Australia and SPARK Sydney,
- 29 Sydney, New South Wales, Australia
- 30 ¹¹ Department of Medicine, Washington University School of Medicine, St. Louis, Missouri,
- 31 United States of America
- 32 ¹² Department of Chemical and Systems Biology, Stanford University, School of Medicine,
- 33 Stanford, California, United States of America
- 34 ¹³ SPARK Global, Stanford University, School of Medicine, Stanford, California, United States
- 35 of America

40

41

- ¹⁴ Independent Scientist, Woodway, Washington, United States of America
- These authors contributed equally to this work.
- 39 *Corresponding author. Email: mochly@stanford.edu (D.M-R)

Abstract

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

COVID-19 emergency use authorizations and approvals for vaccines were achieved in record time. However, there remains a need to develop additional safe, effective, easy-to-produce, and inexpensive prevention to reduce the risk of acquiring SARS-CoV-2 infection. This need is due to difficulties in vaccine manufacturing and distribution, vaccine hesitancy, and, critically, the increased prevalence of SARS-CoV-2 variants with greater contagiousness or reduced sensitivity to immunity. Antibodies from eggs of hens (immunoglobulin Y; IgY) that were administered receptor-binding domain (RBD) of the SARS-CoV-2 spike protein were developed as nasal drops to capture the virus on the nasal mucosa. Although initially raised against the 2019 novel coronavirus index strain (2019-nCoV), these anti-SARS-CoV-2 RBD IgY surprisingly had indistinguishable enzyme-linked immunosorbent assay binding against variants of concern that have emerged, including Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529). This is distinct for sera from immunized or convalescent patients. Culture neutralization titers against available Alpha, Beta, and Delta were also indistinguishable from the index SARS-CoV-2 strain. Efforts to develop these IgY for clinical use demonstrated that the intranasal anti-SARS-CoV-2 RBD IgY preparation showed no binding (cross-reactivity) to a variety of human tissues and had an excellent safety profile in rats following 28-day intranasal delivery of the formulated IgY. A double-blind, randomized, placebo-controlled phase 1 study evaluating single-ascending and multiple doses of anti-SARS-CoV-2 RBD IgY administered intranasally for 14 days in 48 healthy participants also demonstrated an excellent safety and tolerability profile, and no evidence of systemic absorption. As these antiviral IgY have broad selectivity against many variants of concern, are fast to produce, and are a low-cost product, their use as prophylaxis to reduce SARS-CoV-2 viral transmission warrants further evaluation.

Introduction

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

As of January 4, 2022, over 290 million persons with coronavirus disease 2019 (COVID-19) had been identified in 222 countries and territories with an estimated 5.4 million deaths [1]. It is estimated that only 48% of the world population has been fully vaccinated [2], a figure dramatically lower than the 70%-80% believed needed to reach herd immunity to stop the pandemic [3,4]. Furthermore, only 8.5% of people in low-income countries have received at least one vaccine dose to date [2]. The fast emergency regulatory authorizations and approvals of COVID-19 vaccines in various countries were a critical turning point in slowing the spread of the pandemic. However, there remains a global need to develop additional safe, effective, easy-to-produce, and inexpensive prophylaxis to prevent or reduce the risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [5,6]. This need is due in part to the global shortage of essential components necessary for manufacturing the intramuscular mRNA vaccines and the requirement for cold chain storage for distribution. In addition, novel means of prevention are of heightened importance as variants of SARS-CoV-2 such as Delta (B.1.617.20) and Omicron (B.1.1.529) increase contagiousness and evade immunity produced by existing vaccines and previous infection [7-12] and where COVID-19 vaccination is unavailable, especially in resource-poor settings. The emergence of these variants has occurred even in populations with high vaccine uptake and are now the most prevalent COVID-19 strains globally [13]. The main entry route for SARS-CoV-2 is the nasal mucosa, which has high levels of the human angiotensin-converting enzyme 2 (hACE2) receptor that is used by the virus to gain cellular entry [14]. Viral binding to the hACE2 receptor is mediated by the spike (S) protein on

the surface of the viral envelope [15] for all SARS-CoV-2 variants identified so far; even the highly mutated Omicron variant, with 15 mutations in the receptor-binding domain (RBD) of the S protein, is still dependent on hACE2 for its infectivity [16]. Therefore, the nasal mucosa is an excellent site as a critical barrier to reduce SARS-CoV-2 entry; antibodies against the SARS-CoV-2 RBD can compete with viral binding to the hACE2 receptor. In addition, antibodies on epithelial surfaces can greatly inhibit lateral viral motility, agglutinate viral particles, and anchor the virus to the extracellular matrix [17,18], thus making intranasally administered antibodies a potentially important antiviral strategy. Indeed, intranasal antibody prophylaxis has been an effective means against multiple viral pathogens in humans and veterinary applications, including respiratory tract viruses [18]. Thus, covering the nasal mucosa with anti-SARS-CoV-2 antibodies could prevent SARS-CoV-2 infection in naïve individuals and may also reduce viral transmission from an infected individual by reducing levels of active virus.

Because the RBD remains essential for SARS-CoV-2 infection, even for variants of concern, we chose recombinant RBD of the S protein (amino acids 328-533) as the immunogen. We next considered the optimal species to raise anti-SARS-CoV-2 polyclonal antibodies and chose to immunize egg-laying hens to enable fast, low-cost, and high-volume production. Antibodies generated in commercial hens (immunoglobulin Y; IgY) are concentrated in their eggs within 2-3 weeks following vaccination to 50-100 mg/egg, thus yielding up to 35 g of IgY per year; this yield can be up to five times higher (175 g of IgY in one year) when using specific pathogen-free (SPF) hens.

Here, we describe the production of anti-SARS-CoV-2 RBD IgY of the S protein in SPF hens and the characterization of these IgY, including in culture neutralization efficacy against

current pathogenic viral variants and a phase 1 study that evaluated the safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 RBD IgY given by intranasal drops in healthy humans.

Materials and Methods

Study design

The experiments were conducted in 4 parts: 1) production of immunogen (recombinant RBD), immunization of 12 SPF hens, IgY collection from egg yolks, and in vitro characterization of the IgY anti-SARS CoV-2 RBD, 2) GLP blinded safety studies in rat, treated intranasally twice daily for 28 days with a total of 16 mg/kg IgY or vehicle, 3) a preliminary efficacy study of hamsters treated with IgY or phosphate-buffered saline (PBS) for 4 hours before viral challenge, and 4) a placebo-controlled, double-blind phase 1 safety, tolerability, and pharmacokinetic (PK) study conducted in healthy humans using intranasal IgY or vehicle in single-ascending doses followed by multiple doses (3-times daily every 4 hours) for 14 days. Both the single-ascending and multiple-dose parts were followed by a 7-day nontreatment period to further evaluate safety.

Recombinant SARS-CoV-2 RBD

SARS-CoV-2 RBD (residues 328-533) of the 2019 novel coronavirus index virus (2019-nCoV) was expressed in cell-free protein synthesis reactions at Sutro Biopharma, Inc. (South San Francisco, CA) using the XpressCFTM platform [19,20] and was constructed as a carboxy-terminal fusion to a small ubiquitin-related modifier (SUMO) sequence to enable the production of a tagless RBD protein post enzymatic cleavage. The his-SUMO tag was constructed as previously described with an N-terminal his6-tag followed by a GGS-linker and the yeast SUMO protein Smt3 for Ulp1-enabled cleavage [19,20].

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

Briefly, cell-free reactions were prepared by the addition of 37.5% v/v iodoacetamide-treated S30 extract, 5 µg/mL plasmid, and a supermix containing amino acids, nanomicrospheres, and small molecules for energy generation [20]. T7 RNA polymerase was over-expressed in *Escherichia coli* and added to the cell-free reaction as a reagent lysate at <1% v/v. Reactions were carried out in a DASbox stirred tank (Eppendorf) at 250 mL volume with pH, dissolved oxygen, and temperature control. Reactions were run for 16 hours at a temperature of 25°C, pH was controlled at 7.0 using 1 M citrate and 1 M potassium hydroxide, and dissolved oxygen was maintained at 20%.

The XpressCF reaction of SARS-CoV-2-RBD 328-533 was clarified by centrifugation at 10,000 rpm for 20 minutes (Beckman, JLA-10.500 rotor) and filtered through a 0.22-µm membrane filter. The clarified material was loaded onto a 5-mL his-Trap Excel affinity column equilibrated with binding buffer (15 mM Tris-HCl, 500 mM NaCl, pH 8.0). After 20 column volumes were applied to wash unbound impurities, the bound proteins were eluted with 20 mM Tris-HCl, 300 mM imidazole, pH 8.0. The eluted fractions were then analyzed by 4-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and protein concentrations were determined by measured absorbance at 280 nm by NanoDrop (Thermo Fisher Scientific). The his-SUMO tag was removed by Ulp1 protease digestion for 1 hour at room temperature. The digested reaction was analyzed by 4-12% SDS-PAGE to verify full cleavage of the his-SUMO tag before flow-through mode purification by Capto Q (Cytiva). Twenty mM Tris-HCl, pH 8.0, was used to equilibrate the column, and the flow-through containing the cleaved protein was collected. To further purify the CoV-2-RBD, the Capto Q flow-through fraction was bound to a Capto SP ImpRes cation column equilibrated with 20 mM Tris-HCl, pH 8.0. The bound protein was eluted with a 30-column volume linear gradient using elution buffer (20 mM Tris-HCl, 300

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

mM NaCl, pH 8.0). An Amicon Ultra-15, 3kD centrifugal filter was used to concentrate and buffer exchange the target peak fraction into 6% sucrose in PBS at pH 7.2. The final purity of the product was demonstrated by high-performance liquid chromatography (HPLC) analysis. Characterization of the cell-free expressed recombinant RBD using surface plasmon resonance Binding kinetic of cell-free expressed SARS-CoV-2 RBD construct or mammalian expressed his-tagged RBD control (ACROBiosystems SPD-C52H1) were then measured on a Biacore T200 instrument, using Fc-tagged hACE2 receptor protein (ACROBiosystems AC2-H5257). To this end, an anti-human Fc antibody (Jackson ImmunoResearch Labs) was immobilized on all flow cells of a CM5 chip (GE Healthcare). Fc-tagged human ACE2 receptor protein (ACROBiosystems AC2-H5257) was captured at ~100 replication units (RU). Binding of cellfree expressed SARS-CoV-2 S protein RBD construct or mammalian expressed RBD control (ACROBiosystems SPD-C52H1) was measured at concentrations up to 100 nM. Kinetic experiments were performed at 25°C at a flow rate of 50 µL/min. RBD samples were diluted in HBS-EP buffer (Teknova) and injected over the chip for 180 seconds followed by a 420-second dissociation. The chip was regenerated with 10 mM glycine pH 1.5 after each injection. Affinities were calculated using Biacore T200 Evaluation Software. Hen immunization and IgY purification and characterization Nine SPF hens were obtained from Charles River Laboratories and housed in a filtered air, positive pressure barrier room (3 more hens from the same lot were added to the study after 5 months) at Avian Vaccine Services, Charles River Laboratories (Storrs, CT). Each hen was caged individually with access to feed and water. Upon receipt, hens were immunized with an

inoculum containing 50 µg of recombinant cell-free expressed RBD fragment derived from S1 spike protein and water-in-oil adjuvant. Test bleeds were taken before the first immunization and every 2 weeks after the first immunization throughout the project. Serum samples from each hen were tested using an indirect enzyme-linked immunoassay (ELISA) and Western blot. Hens received a boost 14 days after immunization and every 4 weeks after the previous immunization, unless otherwise indicated.

Eggs were collected weekly. Yolks in batches up to 100 eggs/batch were separated and IgY was purified. ELISA titration of IgY binding to full-length S1 (ACROBiosystems, S1N-C5255) expressed in human 293 cells and the cell-free expressed RBD of the SARS-CoV-2 spike protein was performed in 96-well plates. IgY was then purified from yolks. Eggs were collected weekly and egg white was separated from the egg yolk and discarded. Yolks were stored frozen at -20°C. For purification of IgY, yolks were thawed and diluted 1:10 in sterile PBS. The pH was reduced to 5.0 and the yolk solution was incubated at 4°C overnight. Yolk solution was then centrifuged for 10 minutes at 9000 rpm. Supernatant was removed, pooled, pH was increased to 7.0, and final filtration (0.45 μm) was performed.

Hen sera and purified IgY were tested by ELISA and Western blot analysis using both the immunogen (RBD) and full length glycosylated S1 protein (ACROBiosystems, cat# S1N-C5255). Lot Y0120 of purified IgY was derived from 50 yolks, starting 2 weeks after the primary immunization. Lot Y0130 was derived from the next 50 yolks, starting 3 weeks after the primary immunization. Lot Y0140 and above were derived from the next 100 yolks collected over the preceding 2 weeks. Lots of purified IgY were tested by indirect ELISA and Western blot to determine antibody response levels within the yolk after purification as well as affinity to the cell-free expressed RBD fragment of S1 spike protein and the entire glycosylated S1 protein

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

(ACROBiosystems, cat# S1N-C5255). Protein concentration was also measured using the Bradford assay. IgY purity was determined using SDS-PAGE under reducing conditions and stained with Coomassie Blue. ELISA titration of IgY binding to full length and the RBD of the SARS-CoV-2 spike protein was performed as follows: 96-well clear flat bottom polystyrene high-binding ELISA plates (Corning, Cat# 9018) were coated with 100 µl/well of 5 µg/mL recombinant his-tagged (Sino Biological) RBD protein overnight at 4°C. Plates were then washed twice with PBS and blocked with 1% bovine serum albumin (BSA)-PBS. After blocking, 100 μL of serial dilutions of IgY were added to the wells and incubated at room temperature for 2 hours. The plates were then washed twice and incubated with horseradish peroxidase (HRP)-conjugated mouse rat antichicken IgY (Sapphire, Cat# LO-IgY-16-P-0.5) 1:2000 diluted in 0.5% BSA and 0.05% Tween-20 in PBS) for 60 minutes. After 3 final washes using 0.05% PBS-Tween, the plates were read using chemiluminescent substrate (Pierce TMB Substrate Kit, Thermo Fisher, Cat# 34021). Luminescence was read on a plate reader and analyzed with SoftMaxPro 6.0 (Molecular Devices). Hen sera were diluted with 1% BSA at various dilutions and tested in ELISA. One hundred microliters were added to wells and the plate was incubated at room temperature for 1 hour. Plate wells were then rinsed with 1% Tween 20 wash solution, as indicated above. Antichicken HRP conjugate (Invitrogen, cat# SA-19509) diluted 1:5000 was added to each well. The plate was incubated at room temperature for 1 hour, followed by another 1% Tween 20 wash. 3,3',5,5'-tetramethylbenzidine substrate (KPL, cat# 5120-0050) was added to each well and the plate was incubated at room temperature for 15 minutes. Optical density was measured using an ELISA reader (Molecular Devices) at 650 nm.

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Western blot analysis was performed with the cell-free expressed RBD fragment of the index S1 protein or the entire mammalian-expressed S1 protein (ACROBiosystems). One microgram of denatured protein was added to Mini-PROTEAN TGX 4-20% SDS-PAGE. Gel was run at 200V for 45 minutes in Tris-glycine buffer and stained using Simply Blue Safestain (Invitrogen) at room temperature for 1 hour. Gels were destained twice using deionized water. An unstained SDS-PAGE gel was transferred to the polyvinylidene difluoride membrane using Trans-Blot Turbo Transfer System (Bio-Rad Laboratories) and cut into strips. Strips were then stored at -20°C until ready to use. Five percent nonfat dry milk was added to strips and incubated at room temperature for 30-60 minutes. Test bleed sera and IgY were diluted 1:2000 and purified IgY were diluted 1:500 in 0.2 µm-filtered PBS and added to strips. Strips were incubated at room temperature for 2 hours followed by 3 washes in filtered PBS. Rabbit antichicken IgY (H+L) secondary antibody, HRP (Invitrogen) diluted 1:3000 was added to each strip and incubated at room temperature for 1-2 hours. Strips were washed once again in filtered PBS. Opti-4CN substrate (Bio-Rad Laboratories) was added to each strip and incubated at room temperature for up to 30 minutes in a rocking incubator. Strips were washed twice in deionized water and images were taken using Bio-Rad EZ Gel Imager. ELISA evaluation of IgY titer against SARS-CoV-2 variants of concern ELISA titer of the final IgY preparation used in the clinical studies against the Alpha, Beta, Delta, and Omicron-derived RBD [amino acids 319-537; ACROBiosystems SPD-C52H1(index), SPD-C52Hn (Alpha), SPD-C52Hp (Beta), SPD-C525e (Delta), and SPD-C522e (Omicron)]) was carried out as described above.

In culture viral neutralization studies using pseudovirus

11

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

The neutralization assays using pseudovirus were performed at RetroVirox (San Diego, CA). The assay used 3 non-replicative vesicular stomatitis virus (VSV) pseudoviruses carrying a firefly luciferase reporter gene and expressing the following S protein of SARS-CoV-2 on the surface: the index SARS-CoV-2 Hu-1 spike, a truncated spike with a C-terminal 19 amino acid deletion; the Beta variant (K417N/E484K/N501Y/D614G full-length spike); and a D614G spike variant with a full-length sequence of the index spike protein. The IgY preparation or plasma was diluted in Dulbecco's Modified Eagle Medium (DMEM) with 5% fetal bovine serum (FBS) to perform pre-incubation with pseudovirus before addition to target cells. The neutralization assay was performed with HEK 293T-hACE2, a human embryonic kidney cell line overexpressing hACE2. Test item was preincubated for 60 minutes at 37°C with a previously titrated inoculum of pseudovirus. The mixture was then added to 293T-hACE2 cells and infection was allowed for 24 hours. Pseudovirus infection was determined by measuring firefly luciferase activity (RLU, relative light unit ratio) 24 hours after infection. Putative neutralizing antibodies (human sera, purified IgY, or vehicle) were present in the cell culture for the entire duration of the experiment. The ability of the test item to neutralize pseudovirus carrying SARS-CoV-2 spike was compared with samples treated with vehicle alone. Nine concentrations of the IgY sample were tested in duplicates with each variant in 5-fold serial dilutions starting at 10,000 µg/mL. The half-maximal inhibitory concentration (IC₅₀) and 50% neutralization titer (NT₅₀) values for the IgY and positive control human serum were determined using GraphPad Prism software (GraphPad Software). Quality controls for the pseudovirus neutralization assays were performed to determine: 1) signal-to-background values; 2) variation of the assay, estimated as the average of the coefficient of variation for data points for which 50% or greater infection (RLUs) was observed

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

compared to cells with pseudovirus in the presence of vehicle alone, and 3) neutralization with plasma from an individual who received 2 doses of the Moderna (mRNA-1273) COVID-19 vaccine. All controls worked as anticipated for each assay. In culture neutralization studies using live virus At United States Army Medical Research Institute of Infectious Diseases (USAMARIID; Frederick, MD), all work with authentic (live) SARS-CoV-2 was completed in Biosafety Level 3 laboratories following federal and institutional biosafety standards and regulations. Vero-76 cells were inoculated with SARS-CoV-2/Was1 (MT020880.1) at a multiplicity of infection of 0.01 and incubated at 37°C with 5% CO₂ and 80% humidity. At 50 hours post-infection, cells were frozen at -80°C for 1 hour, allowed to thaw at room temperature, and supernatants were collected and clarified by centrifugation at ~2,500 ×g for 10 minutes. Clarified supernatant was aliquoted and stored at -80°C. Authentic (live) SARS-CoV-2/B.1.617.2 at a multiplicity of infection of 1 was incubated for 1 hour at 37°C with serially diluted antibodies. Vero-E6 monolayers were exposed to the antibody-virus mixture at 37°C for 1 hour. Following incubation, viral inoculum was removed and fresh cell culture media was added for an additional 23 hours at 37°C. Cells were washed with PBS, fixed in 10% formalin, and permeabilized with 0.2% Triton-X for 10 minutes. Detection of infection was accomplished using an anti-SARS-CoV-2 nucleocapsid protein detection antibody (Sino Biological), and a goat α-rabbit secondary antibody conjugated to AlexaFluor488. Infected cells were identified using the PerkinElmer Operetta high-content imaging instrument and data analysis was performed using the Harmony software (PerkinElmer). At RetroVirox (San Diego, CA), purified IgY (lot Y0180) was tested against two live SARS-CoV-2 clinical isolates: MEX-BC15/2021 (lineage B.1.617.2, Delta variant) and MEX-

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

BC2/2020 (lineage B.1, carrying the D614G mutation). A virus-induced cytopathic effect (CPE)based neutralization assay was performed by infecting Vero E6 cells in the presence or absence of test items. Vero E6 cells were maintained in DMEM with 10% FBS. Twenty-four hours after cell seeding, test samples were submitted to serial dilutions with DMEM with 2% FBS in a different plate. Then, virus diluted in the same media alone was pre-incubated with test items for 1 hour at 37°C in a humidified incubator. Following incubation, media was removed from cells. Cells were then challenged with the SARS-CoV-2/antibody pre-incubated mix. The amount of viral inoculum was previously titrated to result in a linear response inhibited by antivirals with known activity against SARS-CoV-2. Cell culture media with the virus inoculum was not removed after virus adsorption, and antibodies and virus were maintained in the media for the duration of the assay (96 hours). After this period, the extent of cell viability was monitored with the neutral red uptake assay. The virus-induced CPE was monitored under the microscope after 3 days of infection, and cells were stained with neutral red to monitor cell viability the following day. Viable cells incorporate neutral red in their lysosomes. The uptake of neutral red relies on the ability of live cells to maintain the pH inside the lysosomes lower than in the cytoplasm, a process that requires ATP. Inside the lysosome, the dye becomes charged and is retained. After a 3-hour incubation with neutral red (0.017%), the extra dye is washed away, and the neutral red is extracted from lysosomes by incubating cells for 15 minutes with a solution containing 50% ethanol and 1% acetic acid. The amount of neutral red is estimated by measuring absorbance at 540 nm in a plate reader. Antibodies were evaluated in triplicates using five-fold serial dilutions starting at 10.0 mg/mL. Controls included uninfected cells and infected cells treated with vehicle alone. Some

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

cells were treated with plasma from an uninfected individual who received two doses of Moderna's mRNA COVID-19 vaccine as a positive control. **CPE-based neutralization assay** The average absorbance at 540 nm (A540) observed in infected cells in the presence of vehicle alone was calculated, and then subtracted from all samples to determine the inhibition of the virus-induced CPE. Data points were then normalized to the average A540 signal observed in uninfected cells after subtraction of the absorbance signal observed in infected cells. In the neutral red CPE-based neutralization assay, uninfected cells remained viable and uptake the dye at higher levels than non-viable cells. In the absence of test items, the virus-induced CPE kills infected cells and leads to lower A540 (this value equals 0% inhibition). In contrast, incubation with neutralizing agents prevents the virus-induced CPE and leads to absorbance levels similar to those observed in uninfected cells. Full recovery of cell viability in infected cells represents 100% neutralization of the virus. GMP IgY formulation, analytical studies, and stability Using Good Manufacturing Practice (GMP), anti-S1 RBD IgY was formulated for use as intranasal drops as 0 (placebo control), 5, 10, and 20 mg/mL anti-S1 RBD IgY preparations in sterile 2% microcrystalline cellulose and carboxymethylcellulose sodium at Bravado Pharmaceuticals (Lutz, FL). The suspension was packed in a 1.5-mL dropper bottle and tests for GMP drug product release complied with the relevant standards and methods, including microbiological examination of nonsterile products (USP <1111>, <61> and <62>). All formulated products were 100% stable as measured by physical and analytical properties, including HPLC, when stored for at least 6 months at 2-8°C and about 1 month when stored at room temperature. Ten and 20 mg/mL solutions stored at room temperature showed 100%

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

analytical stabilities for 3 months. However, several samples had some physical visual abnormalities (slight discoloration and opacity) that occurred beginning at 1 month when stored at room temperature. Therefore, all formulated samples used in the subsequent studies were stored at 2-8°C. For stability determination, formulated IgY (20 mL) was chromatographed on a TSK Gel G3000swxl sizing column (with guard column) on HPLC at 0.4 mL/min at room temperature, and eluate was monitored at 214 nm. For the rat toxicity and safety study, and for the human study, we used only 20 mg/mL as the highest dose because it was readily soluble. **GLP** rat toxicity and safety study Thirty-eight female and 38 male >8-week-old Sprague Dawley rats were used in a GLP study conducted at Charles River Laboratories (Spencerville, OH). Rats were identified using a subcutaneously implanted electronic identification chip and were acclimated to their housing for at least 4 days before the first day of dosing. Animals were randomly assigned to groups; males and females were randomized separately and housed in accordance with the USDA Animal Welfare Act (9 CFR, Parts 1, 2 and 3) and as described in the Guide for the Care and Use of Laboratory Animals. For psychological and environmental enrichment, a hiding device, a chewing object, and edible enrichment treats were offered throughout the study and a cycle of 12 hours light and 12 hours dark was maintained. Water and food were freely available. The experimental protocol is summarized in S1-S3 Tables. Detailed clinical observation was conducted once a week and included body weight and food consumption. Ophthalmic examinations were conducted before treatment and during the last week of dosing by a veterinary ophthalmologist and included a short-acting mydriatic solution treatment to each eye to facilitate the ocular examinations. Clinical laboratory

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

assessments included hematology, coagulation, clinical chemistry, urinalysis, and presence of circulating IgY (in serum) tested on pretreatment and Day 28 (last day of treatment) after 4 hours of fasting. Hematology parameters included red blood cell count, hemoglobin concentration, hematocrit, mean corpuscular volume, red blood cell distribution width, mean corpuscular hemoglobin concentration, mean corpuscular hemoglobin, reticulocyte count (absolute), platelet count, white blood cell count, neutrophil count (absolute), lymphocyte count (absolute), monocyte count (absolute), eosinophil count (absolute), basophil count (absolute), large unstained cells (absolute) and other cells (as appropriate). Clinical chemistry parameters included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gammaglutamyltransferase, creatine kinase, total bilirubin, urea nitrogen, creatinine, calcium, phosphorus, total protein, albumin, globulin (calculated), albumin/globulin ratio, glucose, cholesterol, triglycerides, sodium, potassium, chloride, and sample quality. Urinalysis included color, appearance/clarity, specific gravity, volume, pH, protein, glucose, bilirubin, ketones, and blood. Cytokine level measurement and analysis This non-GLP blinded assay was performed on serum by the Immunoassay Team at the Human Immune Monitoring Center at Stanford University (Stanford, CA). Assay kits (RECYMAG65K27PMX Rat) were purchased from EMD Millipore and used according to the manufacturer's recommendations, with modifications described as follows. Briefly, samples were mixed with antibody-linked magnetic beads on a 96-well plate and incubated overnight at 4°C while shaking. Cold and room temperature incubation steps were performed on an orbital shaker at 500-600 rpm. Plates were washed twice with wash buffer in a Biotek ELx405 washer.

Following 1-hour incubation at room temperature with a biotinylated detection antibody, streptavidin-PE was added for 30 minutes while shaking. Plates were washed as described above and PBS was added to wells for reading in the Luminex FLEXMAP 3D Instrument with a lower bound of 50 beads per sample per cytokine. Each sample was measured in duplicate. Custom Assay Chex control beads were purchased from Radix BioSolutions and added to all wells.

Median fluorescence intensity (MFI) data were corrected for plate and nonspecific binding artifacts [20]. Corrected MFI was regressed on time point. Regression analysis employed linear mixed models [21] in SAS®/STAT (SAS Institute) with a separate model fit for each treatment and cytokine, and with separate sets of models with and without gender as a covariate, for 108 models in total. Of the 108 models, 84% met the assumption of normally distributed residuals and 78% for random effects.

IgY in sera of treated rats

The presence of anti-SARS-CoV-2 IgY in sera of rats was evaluated using GLP standards in a qualified ELISA assay at Charles River Laboratories (Reno, NV). ELISA 96-well plates were coated with goat anti-chicken IgY (Thermo Fisher; A16056). After blocking, the plates were incubated with the samples containing anti-SARS-CoV-2 IgY at various concentrations for 1 hour at room temperature. After washing the microplate, rabbit anti-chicken IgY (Thermo Fisher; A16130) - HRP conjugate was added and incubated for 1 hour at room temperature. The ELISA plate was washed and substrate (3,3',5,5'-tetramethylbenzidine) was added to the wells and incubated for 20 minutes. The color development was stopped by the addition of 2N sulfuric acid and color intensity measured in a microplate reader at 450 nm. A calibration curve from the absorbance values was obtained from the standards using a 4-parameter curve fit with a

weighting equation of 1/y2. The concentrations of anti-SARS-CoV-2 IgY in the samples were determined from the calibration curve. After 4 analytical method validations, lower and upper limit of detection, intra- and inter-assay precision and accuracy, dilution integrity, and short-term stability, IgY levels in the blood samples of rats before and after 28 days of treatment were below the limit of detection.

Human tissue cross-reactivity study

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

A GLP study examining human tissue reactivity of the anti-SARS-CoV-2 RBD IgY was conducted at Charles River Laboratories (Frederick, MD) using at least 3 tissues from at least 3 donors (S4 Table). Ten mL of 10 mg/mL or 20 mg/mL IgY control (negative control) and anti-SARS-CoV-2 RBD IgY or an anti-human hypercalcemia of malignancy peptide (amino acid residues 1-34, Sigma-Aldrich; Catalog No. H9148; positive control), each in 1% BSA, were incubated for 1 hour with acetone-fixed human tissues (normal) of at least 3 separate donors after 20 minutes incubation with block solution of PBS + 1% BSA, 0.5% casein and 5% normal rabbit serum. After PBS washes, the secondary antibody (peroxidase [HRP]-conjugated rabbit antichicken IgY; Testing Facility antibody tracking No. A45764; of 2 µg/mL) was added for 30 minutes. After PBS washes, DAB (3,3'-diaminobenzidine) was applied for 4 minutes as a substrate for the peroxidase reaction. All slides were rinsed with tap water, counterstained, dehydrated, and mounted for visualization. For the β2-microglobulin antibody (positive control staining) 1 µg/mL of antibodies were incubated with the slides for 1 hour and bound antibodies were detected with biotinylated secondary antibody (goat anti-rabbit IgG; 2 μg/mL) for 30 minutes, as above. The slides were then visualized on light microscopy.

Virus preparation for the efficacy study in a hamster model of

COVID-19 and quantitation of viral load in the animals

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

Syrian hamsters develop mild-to-moderate disease with progressive weight loss that starts several days after SARS-CoV-2 infection by intranasal inoculation [22,23]. SARS-CoV-2 (strain 2019-nCoV/USA-WA1/2020) was propagated on Vero-TMPRSS2 cells, and the virus titer was determined by plaque assays on Vero-hACE2 and Vero-hACE2-TMPRSS2 cells. Briefly, cells were seeded in 24-well plates, and the next day, virus stocks were serially diluted 10-fold, starting at 1:10, in cell infection medium [Minimum Essential Media (MEM) containing 2% FBS, L-glutamine, penicillin, and streptomycin]. Two hundred and fifty microliters of the diluted virus were added to a single well per dilution per sample. After 1 hour at 37°C, the inoculum was aspirated and a 1% methylcellulose overlay in MEM supplemented with 2% FBS was added. Seventy-two hours after virus inoculation, the cells were fixed with 4% formalin and the monolayer was stained with crystal violet (0.5% w/v in 25% methanol in water) for 1 hour at 20°C. The number of plaques was counted and used to calculate the plaque-forming units (PFU)/mL. Study protocol: hamster infection with SARS-CoV-2 Five- to 6-week-old Syrian golden hamsters (Charles River Laboratories) infected with SARS-CoV-2 as previously described [23] were housed at the Washington University (St. Louis, MO) Biosafety Level 3 facility in HEPA-filtered rodent cages. Before challenge with SARS-CoV-2, all animals received 100 µL of a placebo control fluid or fluid-formulated anti-SARS-CoV-2 RBD IgY (1 mg/50 mL of the 20 mg/mL solution per nare). The amount of nasal anti-SARS-CoV-2 RBD IgY drops was limited by the volume that could be given per nare. Four hours after the delivery, animals were challenged with 10⁴ or 5 x 10⁴ PFU of SARS-CoV-2 (titer determined on Vero-hACE2; see below). The protocol included 18 hamsters in 4 planned groups: Group 1: Control with high 5×10^4 PFU (4 animals); Group 2: Control with 1×10^4 PFU (4 animals); Group 3: Anti-SARS-CoV-2 RBD IgY with 5 x 10⁴ PFU (5 animals); and Group 4: Anti-SARS-

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

CoV-2 RBD IgY with 1 x 10⁴ PFU (5 animals). Note that the viral titer in Vero-hACE2hTMPRSS2 cells, which express the essential protease to liberate the RBD from the S protein on the surface of the virus [24], was subsequently found to be almost 100-fold higher for Groups 1 and 3 (4 x 10⁶ PFU) and Groups 2 and 4 (0.8 x 10⁶ PFU). Animal weight was recorded daily. Three days after challenge, the animals were sacrificed and lungs were collected. The left lobe was homogenized in 1.0 mL of DMEM and the clarified supernatant was used for viral load analysis by plaque assay and quantitative reverse transcription PCR (RT-qPCR). Virus titration assays from hamster samples Plaque assays were performed on Vero-hACE2 and Vero-hACE2-TMPRSS2 cells in 24-well plates. Lung tissue homogenates were serially diluted 10-fold, starting at 1:10, in cell infection medium (DMEM containing 2% FBS, L-glutamine, penicillin, and streptomycin). Two hundred and fifty microliters of the diluted lung homogenates were added to a single well per dilution per sample. After 1 hour at 37°C, the inoculum was aspirated and a 1% methylcellulose overlay in MEM supplemented with 2% FBS was added. Seventy-two hours after virus inoculation, the cells were fixed with 4% formalin, and the monolayer was stained with crystal violet (0.5% w/v in 25% methanol in water) for 1 hour at 20°C. The number of plaques was counted and used to calculate the PFU/mL. To quantify viral load in lung tissue homogenates, RNA was extracted from 100 µL samples using QIAamp viral RNA mini kit (Qiagen) and eluted with 50 µL of water. RNA (4 µL) was used for real-time RT-qPCR to detect and quantify N gene of SARS-CoV-2 using TaqManTM Fast Virus 1-Step Master Mix (Applied Biosystems) or using the following primers and probes for the N-gene, forward: GACCCCAAAATCAGCGAAAT; reverse: TCTGGTTACTGCCAGTTGAATCTG, probe:

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

ACCCCGCATTACGTTTGGTGGACC, or the 5'-UTR, forward: ACTGTCGTTGACAGGACACG, reverse: AACACGGACGAAACCGTAAG, probe: CGTCTATCTTCTGCAGGCTG. Viral RNA was expressed as gene copy numbers per mg for lung tissue homogenates and per mL for nasal swabs, based on a standard included in the assay that was created by in vitro transcription of a synthetic DNA molecule containing the target region of the N gene or 5'-UTR. **Statistical Analysis** Data were analyzed with GraphPad Prism 9.0 and statistical significance was assigned when P values were < 0.05. All tests and values are indicated in figure legends. Phase 1 safety, tolerability, and pharmacokinetic study in humans Study design and dose selection A single-center, randomized, double-blind, placebo-controlled phase 1 study of anti-SARS-CoV-2 RBD IgY given intranasally to 48 healthy adults was conducted at Linear Clinical Research-Harry Perkins Research Institute (Perth, WA, Australia) (Fig. 1, S1 CONSORT Checklist). Written informed consent was obtained from all participants. The study is registered at ClinicalTrials.gov: NCT04567810. The study period was conducted between September 25, 2020 and December 14, 2020. The protocol for this trial and the supporting CONSORT checklist are available as supporting information (S1 Protocol and S1 CONSORT checklist). Figure 1. CONSORT flow diagram of phase 1 single-ascending and multiple-dose study The primary objective of the study was to assess the safety and tolerability of anti-SARS-CoV-2 IgY. A secondary objective was to assess the PK of anti-SARS-CoV-2 IgY. Evaluation of immunoglobulin E (IgE) and anti-IgE antibodies was an exploratory objective.

Healthy male and female participants ≥ 18 and ≤ 45 years old with a body weight ≥ 50 kg and a body mass index ≥ 18.0 and ≤ 32.0 kg/m² were eligible for this study. Females of childbearing potential who were pregnant or lactating or planning to become pregnant during the study and participants with a history of alcohol and drug abuse, current smoking, clinically significant laboratory abnormalities, history of nasal surgical procedures, frequent or recurrent nasal conditions, current use of any nasal preparations, evidence of or history of clinically significant conditions, or positive test for hepatitis B, hepatitis C, human immunodeficiency virus, or SARS-CoV-2 nucleic acid or serology were excluded from participation. Full eligibility criteria are summarized in S1 Protocol.

The master randomization schedule and the associated code break envelope files were produced by an unblinded statistician using a computer-generated (SAS® v9.4 PLAN procedure) pseudo-random permutation procedure. For Part 1, the first two randomization numbers for each cohort were randomly assigned in a 1:1 ratio (anti-SARS-CoV-2 IgY: Placebo) to allow for sentinel dosing, and the remainder of the numbers for each cohort was generated in a 5:1 (anti-SARS-CoV-2 IgY: Placebo) ratio using a permuted blocked randomization with a block size of six. For Part 2, 24 numbers were generated in a 1:1:1:1 ratio (6 mg anti-SARS-CoV-2 IgY: 12 mg anti-SARS-CoV-2 IgY: 24 mg anti-SARS-CoV-2 IgY: Placebo) using a permuted blocked randomization with a block size of six. The block sizes were kept confidential during the study.

The site personnel randomized eligible participants on Day 1 by assigning the next available randomization number for the specific study part to the participant and reporting the randomization number on the case report form. Study drug was prepared by an unblinded pharmacist based on the treatment corresponding to the assigned randomization number on the

randomization schedule that was only available to the pharmacist. In the event of an emergency, authorized personnel were able to unblind a participant through the code break envelope associated with the randomization number assigned to the participant.

In Part 1, participants were randomly assigned to receive a single dose of anti-SARS-CoV-2 RBD IgY antibodies or placebo in a sequential escalating manner. Three groups were sequentially dosed with 8 healthy participants per group (6 active and 2 placebo in each group). Each group in Part 1 included the initial dosing of a sentinel group (1 anti-SARS-CoV-2 RBD IgY and 1 placebo) at least 24 hours before dosing the remaining 6 participants in the cohort (5 anti-SARS-CoV-2 RBD IgY and 1 placebo). The remainder of the cohort were dosed if, in the opinion of the investigator, there were no significant safety concerns identified in the sentinel participants within the first 24 hours after administration of the dose (anti-SARS-CoV-2 RBD IgY or placebo). A Safety Monitoring Committee (SMC) reviewed safety data before each dose escalation. The following regimens were administered: 2 mg anti-SARS-CoV-2 RBD IgY preparation or placebo, 4 mg anti-SARS-CoV-2 RBD IgY preparation or placebo, and 8 mg anti-SARS-CoV-2 RBD IgY preparation or placebo, and 8 mg anti-SARS-CoV-2 RBD IgY preparation or placebo. In Part 1, 2 drops were applied to each nostril as a single administration. A 7-day nontreatment follow-up period assessed safety after completion of the dosing.

In Part 2, participants were randomly assigned to receive multiple daily administrations of anti-SARS-CoV-2 RBD IgY or placebo every 4 hours (3-times daily) for 14 days in a parallel-group manner. Up to 24 healthy participants were randomized to 1 of 4 treatment regimens (6 participants per regimen). The following regimens were administered: 6 mg total daily dose anti-SARS-CoV-2 RBD IgY preparation for 14 days, 12 mg total daily dose anti-SARS-CoV-2 RBD IgY preparation for 14 days, 24 mg total daily dose anti-SARS-CoV-2 RBD IgY preparation for

14 days, and 0 mg total daily dose placebo preparation for 14 days. In Part 2, 2 drops were applied to each nostril every 4 hours (3-times daily). A 7-day nontreatment follow-up period assessed safety after completion of the dosing.

In each part, 3 groups with 8 healthy participants per group (6 active and 2 placebo in each group) were dosed. Safety and tolerability were evaluated using adverse event, physical examination (including vital signs), electrocardiogram, and clinical laboratory data. PK of anti-SARS-CoV-2 RBD IgY was evaluated by measuring serum concentrations pretreatment and at Day 14 when given as multiple doses administered intranasally for 14 days.

The investigational drug was supplied as a liquid preparation in a nose drop bottle containing 1.5 mL anti-SARS-CoV-2 RBD IgY preparation nasal suspension at 5, 10, or 20 mg/mL, or placebo, for intranasal application. Each bottle of nasal drops had enough material for one day of use. The liquid preparation contained anti-SARS-CoV-2 RBD IgY 0.5 mg/100 μL/drop, 1 mg/100 μL/drop, or 2 mg/100 μL/drop. The total maximum daily dose of anti-SARS-CoV-2 RBD IgY used in the present study (24 mg) was based in part on solubility considerations and is less than the daily dose of anti- *Pseudomonas aeruginosa* IgY previously given prophylactically as an oral treatment to prevent pulmonary infections in 17 patients with cystic fibrosis [25]. For the maximum anti-SARS-CoV-2 RBD IgY dose of 4 mg/nare, we calculated a favorable ratio of IgY to viral particles, even when virus covers the nasal pathway.

All participants were provided with a Dose Administration Guide and instructed to "Gently blow your nose before using this drug. Then tilt your head back while sitting or lying down. After the study drug is administered, keep your head tilted for a few minutes. Try not to blow your nose for at least 5 minutes after study drug administration."

Assessments

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

from what was specified in the protocol:

Safety (and tolerability) were evaluated using adverse event, physical examination (including vital signs), electrocardiogram, and clinical laboratory data that included nonfasted collection of a) hematology (hemoglobin, hematocrit, erythrocyte count, mean cell volume, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocyte count), b) serum metabolic panel (sodium, potassium, chloride, total bilirubin, alkaline phosphatase, alanine transaminase, aspartate transaminase, blood urea nitrogen, creatinine, uric acid, phosphorous, calcium, plasma glucose, total protein, albumin, cholesterol, creatinine kinase, c) coagulation, d) urinalysis, and e) urine human chorionic gonadotropin values. Pharmacokinetics following intranasal administration of anti-SARS-CoV-2 RBD IgY were evaluated in the multiple-dose part of the study by measuring serum anti-SARS-CoV-2 RBD IgY concentration (lower limit of quantification, 30 ng/mL) at baseline and 2 hours after final dosing on Day 14, as described above (Charles River Laboratories, Reno, NV). Serum cytokine levels for exploratory analyses were evaluated from the sera of 19 multiple-dose participants before and 2 hours after dosing on Days 1 and 2, as described above (Stanford Human Immune Monitoring Center, Stanford CA). An exploratory analysis was conducted of pretreatment serum total IgE and anti-IgE antibody (mainly anti-ovalbumin) levels in the 24 participants in the multiple-dose part of the trial. **Changes in the Conduct of the Study** All participants were enrolled, treated, and assessed under Protocol CVR001 version 3.0, dated

29 September 2020 (S1 Protocol). The following changes were made to the conduct of the study

 Participants were reconsented to allow for exploratory cytokine analyses on stored blood samples.

Per the study protocol, serum anti-SARS-CoV-2 IgY samples were obtained from participants in the multiple-dose part of the study before dosing and at 0.5, 1, 1.5, and 2 hours after dosing on Days 1 and 14, as well as before dosing and 2 hours after dosing on Days 2, 3, and 4. Because anti-SARS-CoV-2 IgY was not measurable at the time of the theoretical maximum serum concentration at 2 hours postdose on Day 14, the remaining postbaseline PK samples were not analyzed.

Interim Analyses

Before dose escalation in the single-ascending dose cohorts, the SMC was to review all available safety and tolerability data for a minimum of 7 participants who completed the planned safety assessments up to 48 hours after dosing. The SMC was composed of an independent medical monitor, principal investigator, and sponsor's medical representative. The data was to be reviewed blinded, unless the SMC considered it necessary to unblind the data for safety concerns. Before breaking the code per standard procedures, the potential decisions and actions were to be determined. SMC decisions on dose escalation were to be taken in consensus between the members of the SMC. The SMC decisions and their rationale were documented.

Analyses

No formal sample size calculations were done. Based on experience for previous similar studies, the target number of participants to be enrolled was appropriate for the assessment of safety, tolerability, and PK. The planned sample size was 48 participants. A total of 48 participants were enrolled and included in the safety analyses. The analysis of safety variables included all

participants who received study drug. All variables were summarized by descriptive statistics for each treatment group. The statistics for continuous variables included mean, median, standard deviation, and number of observations. Categorical variables were tabulated using frequencies and percentages. The incidence of all reported adverse events and treatment-related adverse events was tabulated by treatment group. Adverse events were also classified by system organ class and preferred term using the Medical Dictionary for Regulatory Activities. Adverse events were to be listed and summarized by treatment group, preferred term, severity, seriousness, and relationship to study drug. In the event of multiple occurrences of the same adverse events with the same preferred term in one participant, the adverse event was counted once as the worst occurrence. Summary statistics for actual values and change from baseline were analyzed for laboratory results by treatment group and scheduled visit. Data summarized by treatment included adverse events, vital signs, electrocardiogram parameters, and clinical laboratory evaluations.

Cytokine measurement and analysis

This non-GLP blinded assay was performed on sera of study participants by the Immunoassay

Team at the Human Immune Monitoring Center at Stanford University (Stanford, CA), as

described for the rat cytokine assay above. The levels of 80 different cytokines were determined.

GLP bioanalytical analysis of IgY in blood samples – toxicokinetic analysis The presence of anti-SARS-CoV-2 IgY in sera of study participants was evaluated using GLP standards in a qualified ELISA assay at Charles River Laboratories (Reno, NV). ELISA 96-well plates were coated with goat anti-chicken IgY (Thermo Fisher; A16056) and, after blocking, were incubated with the samples containing anti-SARS-CoV-2 IgY at various concentrations for

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

1 hour at room temperature. After washing the microplate, rabbit anti-chicken IgY (Thermo Fisher; A16130) - HRP conjugate was added and incubated for 1 hour at room temperature. The ELISA plate was washed and substrate (3,3',5,5'-tetramethylbenzidine) was added to the wells and incubated for 20 minutes. The color development was stopped by the addition of 2N sulfuric acid and color intensity measured in a microplate reader at 450 nm. A calibration curve from the absorbance values was obtained from the standards using a 4-parameter curve fit with a weighting equation of 1/y2. The concentrations of anti-SARS-CoV-2 IgY in the samples were determined from the calibration curve. After 4 analytical method validations, lower and upper limit of detection, intra- and inter-assay precision and accuracy, dilution integrity, and short-term stability, IgY levels in study participants before and after 14 days of treatment were below the limit of detection. **Good Laboratory Practice** The study was performed at Charles River Laboratories following the U.S. Department of Health and Human Services, Food and Drug Administration (FDA), United States Code of Federal Regulations, Title 21, Part 58: Good Laboratory Practice for Nonclinical Laboratory Studies and as accepted by Regulatory Authorities throughout the European Union (OECD Principles of Good Laboratory Practice), Japan (MHLW), and other countries that are signatories to the OECD Mutual Acceptance of Data Agreement. Animal welfare assurance and standards The protocols and any amendment(s) or procedures involving the care and use of animals (hen immunization and rat tolerability studies) were reviewed and approved by Charles River Laboratories Institutional Animal Care and Use Committee before conduct. The hamster efficacy study was carried out following the recommendations in the Guide for the Care and Use of

Laboratory Animals of the National Institutes of Health and the protocol was approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381–01). Stanford Institutional Animal Care and Use Committee did not review the research.

Regulatory and ethics considerations

Ethical review of the clinical trial protocol and any amendments was obtained by Bellberry

Human Research Ethics Committee (the Australian National Review Board) and the clinical trial
was conducted solely at Linear Clinical Research, Perth Australia. Stanford Institutional Review

Board did not review the research. The study was conducted following the protocol and ethical
principles stated in the 2013 version of the Declaration of Helsinki and the applicable guidelines
on Good Clinical Practice, and all applicable federal, state, and local laws, rules, and regulations.

Results

Antigen production

The overall scheme describing the production of anti-SARS CoV-2 IgY antibody to be used as intranasal prophylaxis in humans is shown in Figure 2A. We produced a recombinant protein to immunize hens. A tagless RBD of SARS-CoV-2 (Fig. 2B; index SARS-CoV-2 variant), amino acids 328-533, was produced in a cell-free protein synthesis reaction using *E.coli* extract [19,20,26]. Analysis of the purified CoV-2 RBD protein yielded a single protein band with an apparent molecular weight of 23 kDa (Fig. 2C). The purified SARS-CoV-2 RBD was eluted as a single peak by analytical size-exclusion chromatography with >95% monomer content (Fig. 2C). Bacterial endotoxin contamination was determined to be <0.1 EU/mg by Charles River Endosafe LAL cartridge system.

Integrity of the cell-free (non-glycosylated) SARS-CoV-2 RBD was then verified by kinetic binding to the hACE2 receptor. Binding kinetics and affinity were similar to a mammalian expressed and glycosylated S1 fragment (Fig. 2D) and were consistent with previously described binding affinities, suggesting the RBD expressed cell-free was properly folded and bioactive.

Figure 2. RBD and IgY preparation. (A) Workflow of the study. IgY preparation for intranasal drops as antiviral prophylaxis. (B) Cell-free expressed RBD derived from the Spike protein on the viral envelope of SARS-CoV-2. (C) Characterization of the recombinant protein RBD by ELISA and HPLC. (D) Determination of the affinity of the cell-free expressed RBD (amino acids 328-533) and mammalian-expressed full-length S1 to the hACE2 using Biacore.

Hen immunization with SARS-CoV-2 RBD and IgY

characterization in vitro

Cell-free expressed RBD (Fig. 2B; 50 µg in simple oil emulsion) was injected into 9 SPF hens (46-weeks old) and IgY was extracted from egg yolks using a water-based method 2 weeks after the second immunization and thereafter. The IgY preparation was subjected to protein and Western blot analyses (Fig. 3A). The IgY preparations were >95% pure; a quantitative Western blot analysis demonstrated that this preparation contained less than 2% ovalbumin by weight (Fig. 3A). Chromatography of the IgY preparations on size-exclusion HPLC identified 5 peaks (Fig. 3B); SDS-PAGE and Western blot analysis of the peaks collected between 17 and 30 minutes confirmed that these peaks all contain IgY. The anti-SARS-CoV-2 RBD IgY antibodies recognized both the immunogen, cell-free expressed RBD, and the mammalian-expressed full-length and glycosylated S1 protein (Fig. 3C). One egg yolk of the SPF hens provided about 500 mg of purified IgY and each of >10 independent batches of IgY, purified from 100 eggs, each

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

yielded an average of 47 ± 13 g (SD) of purified IgY (Fig. 3D). There was limited variability in the affinity of the various IgY batches for the S glycosylated protein as judged by ELISA (Fig. 3D; average titer against full-length S1 was 1:18,000). Furthermore, there was almost no difference in titer of individual hens towards the full-length glycosylated S protein, suggesting minimal variability between hens (Fig. 3E, F). Over 11 months, IgY was collected in batches of 100 eggs per preparation with a similar yield of IgY per preparation and a similar response; interruption of immunization for 3 months did not result in a drop in titer (Fig. 3F, right panel). Approximately 300 µg/mL IgY provided 50% neutralization of the index virus in culture (Fig. 3H). Figure 3. IgY purification and characterization. (A) Western blot analysis of the IgY preparation. (B) HPLC profile of the IgY preparation. (C) Western blot analysis of anti-SARS-CoV-2 IgY against RBD fragment and full S1 recombinant protein. (D) IgY yield for various batches derived from 100 eggs each. (E) Western blot data of different lots of anti-SARS-CoV-2 RBD IgY (Y0120-Y0199). Pools of 100 eggs laid by 9 hens over 2 weeks were used for each pool of IgY preparation between May 2020 and March 2021. IgY lot samples were diluted 1:500 followed by a 1:3000 dilution of rabbit anti-IgY HRP conjugate. First left lane shows the Coomassie stain of the same gels. (F) Time-dependent ELISA titers of sera from 3 individual hens following continual immunization (left); arrows indicate immunization timing. Timedependent ELISA titer of 3 hens after immunization was stopped for up to 12 weeks (right). (H) Neutralization of pseudovirus SARS-CoV-2 by various lots of anti-SARS-CoV-2 RBD IgY (conducted at RetroVirox). (I) Neutralization of live index SARS-CoV-2 virus by anti-SARS-CoV-2 RBD IgY (Y0180, conducted at USAMRIID).

Neutralization of SARS-CoV-2 index strain and variants of interest

and concern with anti-SARS-CoV-2 RBD IgY

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

Pseudoviruses are synthetic chimeras that consist of a surrogate viral core derived from a parent virus and an envelope glycoprotein derived from a heterologous virus [26]. Viral neutralization assays in culture (RetroVirox) used non-replicative VSV pseudoviruses carrying a firefly luciferase reporter gene and expressing S of SARS-CoV-2 on the surface of the virion (VSV-S). The neutralization assay was performed with HEK 293T-hACE2, a human embryonic kidney cell line overexpressing hACE2, the receptor of the SARS-CoV-2 virus. First, 5 batches of RBD IgY preparations were tested. The neutralization activity of the purified IgY, defined as the concentration inhibiting 50% of the viruses (IC₅₀) was ~170 µg/mL (Fig. 3G). Importantly, ~10fold higher neutralization activity towards the index SARS-CoV-2 virus was observed when using a live index virus (Fig. 3H). Because at least 13 common variants of SARS-CoV-2 with amino acid mutations in the RBD had emerged since December 2020 [27-29] (Fig. 4A), we tested the activity of the anti-SARS-CoV-2 IgY against several variants (including Beta, Delta, and Omicron; Fig. 4A, B) and D614G, an amino acid substitution outside the RBD that is now found in most variants. Beta, Delta, and Omicron were classified as variants of concern, associated with increased transmissibility or detrimental change in COVID-19 epidemiology, or an increase in virulence or change in clinical disease presentation. First, IgY antibody ELISA titer against Beta RBD was compared with the RBD of the index SARS-CoV-2 virus as well as the most common Alpha variant. ELISA with recombinant full-length S protein or the RBD of the 3 mutants as well as the immunizing RBD fragment of the index virus yielded a virtually identical titer (Fig. 4C). Although the Omicron variant still

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

uses the hACE2 receptor to infect human cells [10,30], the RBD contains a total of 15 mutations compared to the index virus, 11 of which were not found in the previous variants (Fig. 4A, B). Yet, the ELISA titer of IgY against the Omicron RBD was also equivalent or slightly better than that towards the RBD of the index virus (Fig. 4D). Next, we tested the neutralization titer of anti-SARS-CoV-2 RBD IgY (lot Y0180) against the RBD of the index, Alpha, and Beta variants, thus including all the amino acid substitutions within the RBD also found in the RBD of Gamma, Zeta, Eta, Theta, Iota, and Mu variants and 1 of the 2 substitutions in the Kappa variant (Fig. 4A). The IC₅₀ of the VSV-S pseudovirions for the index strain and Beta variant were virtually identical: 668 µg/mL for the index strain, 568 μ g/mL for Beta (Fig. 4E), and 2-fold lower for Alpha (IC₅₀ = 302 μ g/mL; Fig. 4E). RetroVirox also provided data using plasma from a single Moderna-vaccinated individual for a titer comparison of neutralization with anti-SARS-CoV-2 RBD IgY, tested with 3 of the variants. In a side-by-side study, the IC₅₀ generated with the human plasma from a recipient of the mRNA Moderna vaccine (2 doses; index SARS-CoV-2) showed the highest titer against the index virus, followed by a 2.8-fold drop in titer towards Alpha and a 6.7-fold lower titer for Beta (Fig. 4F). The anti-SARS-CoV-2 IgY preparation was similarly effective against the Delta variant compared with the index strain (Fig. 4G). The assays show that Y0180 displays similar neutralizing activity against both isolates; IC₅₀ values generated were 635 μg/mL (Delta) and 739 μg/mL (index virus). Plasma from a Moderna-vaccinated individual was also tested in parallel with both isolates. NT₅₀ values generated with this plasma against the variants were 1:1274 (Delta pseudovirus) and 1:1091 (index pseudovirus). The neutralization activities of the antibody and control plasma against both variants were also confirmed by microscopy evaluating the

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

virus-induced CPE in infected cell monolayers (Fig. 4H). The human serum had a similar degree of neutralization against the index pseudovirus and Delta (Fig. 4H) when tested at a dose that is three times higher than that required for 50% neutralization (1:640 in Fig. 4H, middle panels, vs. 1:2,000 in Figure 4F). In contrast, anti-SARS-CoV-2 IgY tested at 400 µg/mL (Fig. 4H, right panels), a dose below that required for 50% neutralization (~650 µg/mL; Fig. 4G), was equally effective against both variants. Together, these data indicate that the spectrum of the polyclonal anti-SARS-CoV-2 RBD IgY displays sufficient diversity so that none of the common point mutations in the RBD associated with a greater transmission rate of the virus affected the neutralization efficacy of these most common SARS-CoV-2 variants of concern. Figure 4. Common variants of SARS-CoV-2 and anti-SARS-CoV-2 IgY interaction with them. (A) A scheme depicting locations of mutated amino acids in Alpha through Mu variants of SARS-CoV-2, focusing on the RBD domain only. Each color bar indicates the amino acid in the index virus that was mutated in the variant. (B) Spike protein of SARS-CoV-2 Alpha, Beta, Delta, and Omicron are shown from left to right. Molecular Operating Environment was used to create the figure [31]. The location of mutations in the structure of the S protein trimer of SARS-CoV-2 (PDB ID: 7A98) for 4 of the common variants are indicated in red and glycosylation sites are indicated in pink throughout the S protein. Blue ribbon indicates RBD (amino acids 328-533) and the orange ribbon indicates receptor binding motif (amino acids 437-508). (C) Binding of anti-SARS-CoV-2 RBD IgY to recombinant S1 full length (FL) of the index virus, the RBD of the Alpha and Beta variants, and the immunizing RBD of the index virus by ELISA. (D) Binding of anti-SARS-CoV-2 RBD IgY to the index virus and Omicron variant (B.1.1.529) RBD domain using ELISA. (E) Neutralization of pseudovirus (VSV-S) SARS-CoV-2 carrying S protein of index pseudovirus, Alpha, or Beta variants by anti-SARS-

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

CoV-2 RBD IgY. (F) Neutralization of pseudoviruses listed in (E) by Human anti-SARS-CoV-2 RBD. (G) Neutralization of live index or Delta viruses by anti-SARS-CoV-2 IgY against the RBD. (H) Neutralization of live D614G vs. Delta variants by human serum of immunized individual or by anti-SARS CoV-2 IgY. Microscopic evaluation of monolayers of Vero E6 cells after 96 hours infection with the indicated authentic (live) SARS-CoV-2 variant. Images from infected cells are shown after 4 days of infection with SARS-CoV-2 variants in the absence or presence of test items. Top three panels: Infection in the presence of MEX-BC2/2020 and bottom three panels: infection with the Delta variant each in the presence of vehicle alone, serum of a person immunized twice with the Moderna (mRNA-1273) vaccine or anti-SARS CoV-2 RBD IgY, as indicated, all at the indicated concentration (neutralization experiments in panels E-H were conducted by RetroVirox using pseudovirus or live virus, as indicated). Except when indicated, the studies were done over several months; therefore, the absolute titers in the ELISA and neutralization studies were not identical. However, each experiment included the same positive control; index RBD for ELISA and index virus for neutralization assays. Efficacy study in a hamster model of COVID-19 We did not find in vivo efficacy of anti-SARS-CoV-2 RBD IgY in the Syrian golden hamster COVID-19 model against a challenge with a titer of 0.8 or 4 x 10⁶ of SARS-CoV-2 virus, likely because the amount of virus we employed was too high. Lung viral load after 3 days was comparable between the control treatment group and the anti-SARS-CoV-2 RBD IgY treatment group, but body weight loss was more severe in control animals (S1 Fig). Rat toxicity and safety study All 8-week-old Sprague Dawley rats (10 males and 10 females) in the 28-day GLP safety study (Fig. 5A) survived to scheduled euthanasia with no mortality, test article-related organ weight changes, or gross or microscopic findings (see Fig. 5B). There were also no differences between

female and male groups in each treatment arm. The GLP-qualified assay detected no anti-SARS-CoV-2 RBD IgY in the sera of animals after 28 days of daily treatment with 4 mg anti-SARS-CoV-2 RBD IgY (lower limit of detection of 30 ng/mL).

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

There was no evidence of significant systemic immune activation in the rats (20/group) treated as above by measuring changes in levels of 27 proinflammatory serum cytokines after anti-SARS-CoV-2 RBD IgY administration (Fig. 5C). When comparing posttreatment (Day 1 at 4 hours and Day 28 at 24 hours after twice-daily treatments) to pretreatment serum levels (Day 1, time 0; D1 H0), there were no changes for most of the cytokines (22 of the 27 tested) in both placebo- and IgY-treated groups at any time. Compared with D1 H0, we detected a transient, slight increase in interleukin-1 (IL-1) beta and monocyte chemoattractant protein-1 (MCP1) on Day 1, 4 hours after anti-SARS-CoV-2 RBD IgY administration. A similar trend that did not reach significance was also observed in the placebo group at the same time; increases in IL-1 beta and MCP1 were not seen at any other time. There was a significant increase in interferoninducible protein 10 (IP10) on Day 1, 4 hours after the first treatment compared to D1 H0, observed in both treatment and placebo group. A significant decrease in D1 H24 in the placebo arm was observed only for RANTES (Fig. 5C). Nonetheless, none of these changes in cytokines were observed in the rats at other time points. Together, our data show that long-term twice-daily administration of 4 mg/mL IgY (or 16 mg/kg) up to 28 days in rats has excellent safety and tolerability with no evidence of systemic immune activation.

Figure 5. Preclinical toxicity of 28-day treatment with anti-SARS-CoV-2 RBD IgY in rats. (A) Study design. (B) Summary of findings. (C) Serum levels of 27 cytokines over time in rats treated with IgY (Tx) or vehicle/placebo (PL). Data are provided for Day 1 before treatment (D1H0); Day 1, 4 hours after the treatment (D1H4); 24 hours after the two treatments,

6 hours apart, at 24 hours after the first treatment (D1H24); 28 days of twice-daily treatments and 4 hours of the treatment of that day (D28H4); and 28 days of twice-daily treatments and 24 hours of the treatment of that day (D28H24). Red indicates a statistical difference with a false discovery rate (FDR) significant p-value (p < 0.05). **Human tissue cross-reactivity study** We determined potential cross-reactivity of the anti-SARS-CoV-2 RBD IgY protein to a full panel of human tissues (at least 3 donors per tissue; see S4 Table for a list of human tissues tested for reactivity). Anti-SARS-CoV-2 RBD IgY reactivity at two concentrations (20 and 10 µg/mL) was compared with control polyclonal chicken IgY antibodies (negative control), and with anti-human macroglobulin (positive control for staining). No specific binding was observed with the anti-SARS-CoV-2 RBD IgY to any of the human tissue panels examined, including human nasal cavity and lung (see Fig. 6). Figure 6: Lack of cross-reactivity of anti-SARS-CoV-2 RBD IgY with human tissues. Immunohistochemical testing of anti-SARS-CoV-2 RBD IgY (top row), control IgY (middle row; negative control), and anti-human macroglobulin antibodies (bottom row; positive control) with human nasal mucosa (left two panels) and human lungs (right two panels). Bars provide a magnification scale. **Phase 1 Clinical Trial Results** Forty-seven of 48 enrolled participants completed the study drug treatment period and planned study visits. One participant in the multiple-dose part was withdrawn from the study after receiving 3 doses (Day 1) of placebo due to a concurrent upper respiratory tract infection, judged

Baseline Demographics

to be unrelated to study drug by the investigator.

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

Study participants ranged in age from 20 to 43 years (median, 25.5) in the single-dose part of the study and 18 to 40 years (median, 23.0) in the multiple-dose part (Tables 1,2). Female participants comprised 75% of the population in the single-dose study segment and 46% in the multiple-dose study segment. Demographics are summarized in Tables 1 and 2.

Table 1. Demographics of participants in single-ascending dose group (Part 1).

| Anti-SARS-CoV-2 IgY | | | | | |
|---------------------------|--------------|--------------|--------------|--------------|------------------|
| | 2 mg | 4 mg | 8 mg | Placebo | All Participants |
| | N=6 | N=6 | N=6 | N=6 | N=24 |
| Age, years | | | | | |
| Mean (SD) | 28.8 (7.99) | 27.3 (4.76) | 27.7 (5.65) | 22.7 (2.34) | 26.6 (5.72) |
| Median (range) | 26.5 (20-43) | 28.0 (21-33) | 27.5 (20-37) | 22.0 (20-27) | 25.5 (20-43) |
| Gender, n (%) | | | | | |
| Female | 4 (66.7) | 4 (66.7) | 4 (66.7) | 6 (100) | 18 (75.0) |
| Male | 2 (33.3) | 2 (33.3) | 2 (33.3) | 0 | 6 (25.0) |
| Ethnicity, n (%) | | | | | |
| Hispanic or Latino | 1 (16.7) | 0 | 0 | 0 | 1 (4.2) |
| Not Hispanic or Latino | 5 (83.3) | 6 (100) | 6 (100) | 6 (100) | 23 (95.8) |
| Race, n (%) | | | | | |
| Asian | 2 (33.3) | 1 (16.7) | 0 | 0 | 3 (12.5) |
| Native Hawaiian or Other | 0 | 0 | 0 | 1 (16.7%) | 1 (4.2%) |
| Pacific Islander White | 4 (66.7) | 5 (83.3) | 6 (100) | 5 (83.3) | 20 (83.3) |

Table 2: Demographics of participants in the multiple-dose group (Part 2).

| Anti-SARS-CoV-2 IgY | | | | | |
|------------------------|--------------|--------------|--------------|--------------|------------------|
| | 2 mg TID | 4 mg TID | 8 mg TID | Placebo TID | All Participants |
| | N=6 | N=6) | N=6 | N=6 | N=24 |
| Age, years | | | | | _ |
| Mean (SD) | 26.0 (8.37) | 21.8 (2.14) | 27.5 (6.92) | 25.3 (6.41) | 25.2 (6.33) |
| Median (range) | 23.0 (18-40) | 22.0 (19-25) | 25.0 (21-37) | 25.0 (18-36) | 23.0 (18-40) |
| Gender, n (%) | | | | | |
| Female | 1 (16.7) | 4 (66.7) | 2 (33.3) | 4 (66.7) | 11 (45.8) |
| Male | 5 (83.3) | 2 (33.3) | 4 (66.7) | 2 (33.3) | 13 (54.2) |
| Ethnicity, n (%) | | | | | |
| Hispanic or Latino | 0 | 0 | 1 (16.7) | 1 (16.7) | 2 (8.3) |
| Not Hispanic or Latino | 6 (100) | 6 (100) | 5 (83.3) | 5 (83.3) | 22 (91.7) |

| Race, n (%) | | | | | | |
|-------------------------|----------|----------|----------|----------|-----------|--|
| Asian | 1 (16.7) | 2 (33.3) | 2 (33.3) | 2 (33.3) | 7 (29.2) | |
| Black or African Americ | an 0 | 0 | 0 | 1 (16.7) | 1 (4.2) | |
| White | 5 (83.3) | 4 (66.7) | 4 (66.7) | 3 (50.0) | 16 (66.7) | |

tid = 3-times daily

868

869

870

871

872

873

874

875

Safety and tolerability

The overall incidence of treatment-emergent adverse events was 29% (7 of 24 participants; Table 3) in the single-dose part of the study and 58% (14 of 24 participants; Table 4) in the multiple-dose part of the study, with similar incidence rates between anti-SARS-CoV-2 RBD IgY (42%) and placebo (50%) groups (Tables 3, 4). The most frequent treatment-emergent adverse event was headache, with similar rates between placebo (17%) and anti-SARS-CoV-2 RBD IgY (14%) (Tables 3,4).

Table 3. Adverse events by preferred term- single ascending-dose study (Part 1).

| | Anti-SARS-CoV-2 IgY | | | | |
|------------------------------|---------------------|-------------|-------------|-------------|------------------|
| | 2 mg | 4 mg | 8 mg | Placebo | All Participants |
| | (N=6) | (N=6) | (N=6) | (N=6) | (N=24) |
| | n (%) E | n (%) E | n (%) E | n (%) E | n (%) E |
| Participants with ≥1 TEAE | 1 (16.7%) 1 | 2 (33.3%) 2 | 2 (33.3%) 2 | 2 (33.3%) 2 | 7 (29.2%) 7 |
| MedDRA Preferred Term | | | | | |
| Fatigue | 0 | 0 | 1 (16.7%) 1 | 1 (16.7%) 1 | 2 (8.3%) 2 |
| Erythema | 0 | 0 | 1 (16.7%) 1 | 0 | 1 (4.2%) 1 |
| Headache | 0 | 1 (16.7%) 1 | 0 | 0 | 1 (4.2%) 1 |
| Sneezing | 0 | 1 (16.7%) 1 | 0 | 0 | 1 (4.2%) 1 |
| Tension headache | 1 (16.7%) 1 | 0 | 0 | 0 | 1 (4.2%) 1 |
| Thermal burn | 0 | 0 | 0 | 1 (16.7%) 1 | 1 (4.2%) 1 |

E = number of events; n = number of participants; TEAE = treatment-emergent adverse event

Table 4. Adverse events by preferred term- multiple-dose study (Part 2).

| | Anti-SARS-CoV-2 IgY | | | |
|------|---------------------|--------------|-------------|------------------|
| 2 mg | TID 4 mg 7 | TID 8 mg TII | Placebo TID | All Participants |
| (N= | (N=6) | (N=6) | (N=6) | (N=24) |

| | n (%) E |
|--------------------------------|-------------|-------------|-------------|-------------|---------------|
| Participants with ≥1 TEAE | 4 (66.7%) 7 | 2 (33.3%) 3 | 4 (66.7%) 5 | 4 (66.7%) 5 | 14 (58.3%) 20 |
| MedDRA Preferred Term | | | | | |
| Headache | 0 | 0 | 3 (50.0%) 3 | 2 (33.3%) 2 | 5 (20.8%) 5 |
| Upper respiratory tract infect | 0 | 0 | 1 (16.7%) 1 | 1 (16.7%) 1 | 2 (8.3%) 2 |
| Contusion | 0 | 0 | 0 | 1 (16.7%) 1 | 1 (4.2%) 1 |
| Dental discomfort | 1 (16.7%) 1 | 0 | 0 | 0 | 1 (4.2%) 1 |
| Dizziness | 1 (16.7%) 1 | 0 | 0 | 0 | 1 (4.2%) 1 |
| Ear pain | 1 (16.7%) 1 | 0 | 0 | 0 | 1 (4.2%) 1 |
| Epistaxis | 1 (16.7%) 1 | 0 | 0 | 0 | 1 (4.2%) 1 |
| Eyelid irritation | 0 | 0 | 1 (16.7%) 1 | 0 | 1 (4.2%) 1 |
| Injection site haematoma | 1 (16.7%) 1 | 0 | 0 | 0 | 1 (4.2%) 1 |
| Nasal congestion | 0 | 0 | 0 | 1 (16.7%) 1 | 1 (4.2%) 1 |
| Parosmia | 0 | 1 (16.7%) 1 | 0 | 0 | 1 (4.2%) 1 |
| Presyncope | 1 (16.7%) 1 | 0 | 0 | 0 | 1 (4.2%) 1 |
| Rhinorrhoea | 0 | 1 (16.7%) 1 | 0 | 0 | 1 (4.2%) 1 |
| Skin abrasion | 0 | 1 (16.7%) 1 | 0 | 0 | 1 (4.2%) 1 |
| Tenderness | 1 (16.7%) 1 | 0 | 0 | 0 | 1 (4.2%) 1 |

E = number of events; n = number of participants; TEAE = treatment-emergent adverse event

All adverse events were mild (grade 1) in severity. No serious adverse event or labrelated adverse event was reported, and there was no dose dependency of adverse events
observed. Furthermore, no participant receiving anti-SARS-CoV-2 RBD IgY had an adverse
event of nasal irritation or nasal congestion. There were no clinically significant observations or
trends noted in laboratory assessments, vital signs, physical exam findings, or electrocardiograms
during the study.

Pharmacokinetics

PK analyses indicated no evidence of serum anti-SARS-CoV-2 RBD IgY above the lowest detection levels of 30 ng/mL (using a GLP study at Charles River Laboratories) in the 18 participants who received anti-SARS-CoV-2 RBD IgY in the multiple-dose part of the study.

Serum cytokines

Levels of 80 different cytokines in sera of 19 participants of the multiple-dose part were

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

tested before treatment (D1 pre-dose), 2 hours after dosing on day 1 (D1 H2); day 2, before treatment (D2 pre-dose), and 2 hours after the first dosing on day 2 (D2 H2, Fig. S2). There were slight but statistically significant decreases (red histograms) in 10 of the 80 cytokines (Fig. S2). These slight declines in CCL27, CXCL9, IL23, IL27, LIF, MIP5, RESISTIN, TNFα, TNFβ, and TNFRSF6 were noted only in the 12 mg/day group compared to the pretreatment levels (Fig. S2). These declines also occurred only 2 hours after the first dose (D1 H2) and were not sustained, except for MIP5 (Fig. S2). There was also a small decrease in IL3, 2 hours after the first dose of 6 mg/day group anti-SARS-CoV-2 RBD IgY, but there were no changes in this cytokine at any other times or doses (Fig. S2). These slight changes, which were also not sustained or dose dependent, were judged to be artifactual. Overall, there were no clinically relevant increases in serum cytokines at any time for any of the treatment groups (6, 12, or 24 mg total daily dose of anti-SARS CoV-2 RBD IgY for 14 days). IgE and anti-IgE The anti-SARS-CoV-2 IgY preparation contains ovalbumin. Although participants with egg allergies were excluded from the trial, an exploratory analysis was conducted of pretreatment serum total IgE and anti-IgE antibody (mainly anti-ovalbumin) levels in the 24 participants in the multiple-dose part of the trial. No participant had detectable serum egg-white specific IgE antibodies (all <0.35 kU/L). **Discussion** Despite recent successes in generating highly effective COVID-19 vaccines, there is an ongoing need for widely available and safe antiviral strategies that reduce infection and transmission worldwide. Limitations to current vaccines include global vaccine availability and affordability, vaccine hesitancy, and rapidly emerging highly infective viral strains that escape vaccine-

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

induced immunity. This has been particularly apparent following the emergence of Delta and Omicron. The latter variant was first detected in specimens collected on November 8, 2021 [32], and within a few weeks became the dominant SARS-CoV-2 variant in the United States [33]. Both convalescent sera from early strain-infected patients and fully vaccinated individuals exhibited a low neutralization capacity against Omicron [9-12]; a reduction of 30 to 40-fold in neutralization titers was reported. Furthermore, of eight currently authorized or approved monoclonal antibodies, seven did not neutralize the Omicron variant and one had a 3-fold reduction in neutralization titer [11]. These data highlight the need for alternative and complementary approaches to curb COVID-19. Here, we describe the production of the first chicken egg yolk-derived anti-index SARS-CoV-2 RBD IgY polyclonal antibodies as an intranasal drop product for humans with equal in vitro activity against all variants of concern. These IgY were raised in SPF hens and showed an excellent safety profile when given intranasally by drops to rats for 28 days (4 mg/day). No toxicity, innate inflammatory response, or systemic exposure to IgY were noted in this GLP study. In 48 healthy adult participants, anti-SARS-CoV-2 RBD IgY given intranasally at singleascending doses of 2, 4, and 8 mg and as total daily doses of 6, 12, and 24 mg for 14 days also had a highly favorable safety and tolerability profile. Importantly, no participant receiving intranasal anti-SARS-CoV-2 IgY in the multiple-dose phase had measurable levels of anti-SARS-CoV-2 RBD IgY in their sera, reflecting the absence of systemic absorption of topically administered IgY following intranasal application. We also found no evidence of a systemic inflammatory immune response triggered by the topical treatment with anti-SARS-CoV-2 RBD IgY in humans, and no detectable increase in 80 sera cytokines.

Hen-derived IgY antibodies have several advantages for topical use in humans; these antibodies do not bind the Fc receptor or rheumatoid factor or activate the human complement cascade [34], thus greatly reducing the risk of severe immune responses. These features support the clinical applications of IgY for nasal treatment in a wide range of persons, including the elderly, immunocompromised, and children. IgY has been beneficial with favorable safety and tolerability when given prophylactically in both animal models and clinical settings of viral diseases, including respiratory infections (reviewed in [35]). Overall, available data to date suggest that IgY given by nonparenteral administration does not have unwanted off-target proinflammatory effects and is nontoxic to humans, thus permitting potential clinical applications in diverse populations and diseases.

The potential use of IgY from hens immunized with inactivated virus [36], full length recombinant S protein [37-40], or N protein [41] has been explored with studies evaluating neutralization of the virus in cells, with IC50 values of 10 mg/mL [36], 1 mg/mL [37], 16.8 mg/mL [38], and 0.27 mg/mL [39]. However, the ability of these egg-derived antibodies to neutralize other common SARS-CoV-2 variants has not been evaluated and their safety profile in animals or humans has not been assessed.

Intranasally administered proteins are removed from the mucosal surface through ciliary movement [37, 42], which was the basis for using a 3-times daily (every 4 hours) regimen in our phase 1 study. The anti-SARS-CoV-2 RBD IgY was designed to capture and immobilize SARS-CoV-2 on the nasal mucosa, preventing the virus from binding to and spreading across the nasal mucosa, and also preventing the transmission of the virus to other individuals. Intranasal delivery of mammalian immunoglobulins as antiviral agents has been extensively tested in humans [43-48]. Human immunoglobulins G (IgG) and A (IgA) given intranasally are well tolerated [43-48],

stems from the observation that levels of lung hACE2 are much lower than in the nose; infection of lung tissue is >5 orders of magnitude lower compared with nasal mucosa [49,50]. Therefore, inhibition of viral entry at the nose is likely the correct target site for optimal efficacy.

Our product is egg-derived immunoglobulins, which could contain potentially antigenic residual chicken proteins. However, it is not indicated for those who are allergic to egg yolks. Note also that most humans are exposed to egg-derived antigens through their diet and are not allergic. Furthermore, anaphylaxis for those who consume eggs regularly is rare. However, the safety and tolerability of hen-derived IgY as intranasal treatment in humans have not been described despite their extensive use in a variety of routes in animals and aquaculture [35,51].

Several other studies have examined anti-COVID-19 intranasal prophylaxis, mostly in animal models [52-58]. These prophylaxes include polymer barriers, active vaccines, existing antiviral drugs, inhibitors of protease-induced activation of the virus, antiseptics, antimicrobial agents, and antibodies. Most relevant for comparison with our study is the use of neutralizing antibodies. In one study, intranasal treatment with a monoclonal human antibody (500 µg in100 µL/nare) 12 hours after infection in hamsters inoculated with 5 x 10⁴ median tissue culture infective dose (TCID₅₀) of SARS-CoV-2 decreased clinical disease signs and improved recovery during 9 days of infection compared with control antibody-treated hamsters [58]. However, in contrast to our study, there was a substantial systemic exposure to the human antibody 24 hours after a single intranasal treatment with 2.5 mg; serum levels of the treated antibodies in that study were 210 ng/mL vs. below detection levels (30 ng/mL) in our study following administration of 4 mg IgY antibodies intranasally daily for up to 28 days. Therefore, the benefit of the treatment in their study [58] could have been due to neutralization of the virus that had

entered the body rather than blocking entry of the virus at the nasal mucosa. Similarly, a single intranasal monoclonal immunoglobin M (IgM) antibody administration in a mouse model of COVID-19 was highly efficacious when mice were infected with 10⁴ PFU [56]. Human IgM systemic exposure was also noted in mice treated with human IgM monoclonal antibody anti-SARS-CoV-2, although the study attributed the protection to the persistent presence of the antibody at the nasal cavity for over 48 hours based on fluorescent tag measurement [56]. Such long persistence of levels of IgM in the nasal cavity is at odds with other studies, including when using 99mTc-labeled albumin particles or fluorescently labeled IgY antibodies that showed residence time of 2-4 hours [37]. If the long persistence is not an artifact of the method, it may suggest a unique benefit of IgM treatment as COVID-19 prophylaxis. Note, however, that with one exception [56], none of these studies assessed the cross-reactivity of antibodies against the variants.

Our work shows that, although the IgY was raised against the ancestral (index) strain RBD, the repertoire of the antibodies raised in hens was diverse and polyclonal so that binding affinities measured by ELISA for the single (Alpha), double (Delta), and triple amino acid (Beta) substitutions, or the Omicron variant with 15 amino acid substitutions in the RBD, were not different from the affinity for the index RBD or full-length S protein (Fig. 4C, D). We then confirmed that there was no difference between Alpha, Beta, and Delta variants, and the index strain in a neutralization assay in culture using a VSV-S pseudovirus or live virus (Fig. 4E, G), whereas a reduced neutralization activity of human serum was observed in side-by-side experiments (Fig. 4F, H). The viral neutralization studies reported here were conducted by a commercial provider (RetroVirox) and by an established laboratory at the USAMRIID, both

comparing the results with either convalescent sera or an immunized human, for relative titer evaluation.

The culture neutralization titer of anti-SARS-CoV-2 RBD IgY is lower than the human anti-SARS-CoV-2 sera (e.g., Fig. 4F vs. E). However, this may reflect the need for protease-induced RBD exposure in the full-length S protein for binding by IgY, which might not occur effectively in the culture model. A comparison of titer values between our product and sera from an immunized person can also be calculated based on values of IgG levels in human sera (~15 mg/mL); a titer of 1:2,000 (Fig. 4F; dashed line) is equivalent to ~7 ug/mL or 100-fold higher IgG titer than our IgY (Fig. 4E; ~600 ug/mL). However, as the dose of the IgY anti-SARS-CoV-2 preparation in humans is planned to be 4 mg/dose, more important is the equal potency of the IgY towards the various variants when used even at ~1/10 of the intended IgY dose (Fig. 4H).

Another potentially important difference between our findings and the previously published study is the antigen used to raise the antibodies. When expressed in mammalian cells, the full-length S1 protein has at least 22 glycosylation sites per S monomer [59]. As glycosylated amino acids are more immunogenic, the affinity of the human antisera may reflect binding to the glycosylated determinants of the protein. However, as glycosylation sites in the S1 protein are heavily mutated and new sites may be formed in many of the variants [28], immune reactivity that is biased towards glycosylated sites may lead to loss of activity as the virus mutates. This will not occur when the non-glycosylated RBD is used as the immunogen, as we have done in our study using cell-free expressed RBD [20,21]. Supporting the negative impact of glycosylated antigen, increased immunogenicity of protein antigens after removal of glycosylation sites has been previously shown for hepatitis C virus envelope antigen-based vaccines [60]. Furthermore, the apparent higher titer in the neutralization assay may be biased if the tested virus has the same

glycosylation sites as that used as an immunogen in vaccinated individuals; many studies use the original viral isolates rather than the common current variants.

An important feature of our product is the ease of developing prophylaxis that can be quickly and inexpensively produced. We found that 24 mg total daily dose (divided into three equal doses) of intranasal anti-SARS-CoV-2 IgY for 14 days had an excellent safety profile in humans; this daily dose represents ~1/20 of one egg of immunized SPF hen and ~1/5 of an egg of commercial hen, underscoring that such an IgY dose is feasible for both production cost and effort.

There are some limitations to our studies. Our phase 1 clinical trial in healthy volunteers was to assess initial safety, tolerability, and PK of anti-SARS-CoV-2 IgY and was not designed to evaluate efficacy. In addition, we were unable to obtain in vivo data showing viral neutralization (Fig. S1.). This may reflect using too much virus in this animal model of COVID-19; our study used 8 x 10^5 or 4 x 10^6 , vs. 1 or 5 x 10^4 TCIDso [55,58]. In addition, our intranasal formulated IgY preparation was viscous to obtain better delivery in humans. As hamsters are obligatory nose-breathers, they may have blown out the formulated IgY. Finally, the virus that was delivered in 50 μ L of liquid directly into each nare may have washed out some antibodies. Another limitation in our study is that the neutralization studies comparing the hen IgY vs. human sera were not comprehensive and included only 1 or 2 human samples. Nevertheless, our study is the first to demonstrate the broad selectivity of anti-SARS-CoV-2 IgY against all the current variants of concern and a favorable safety profile when used chronically as intranasal drops in rats and humans.

There are also several advantages for the use of IgY as prophylaxis against other pathogens besides SARS-CoV-2 that cause disease in humans. As we noted above, IgY

generation is inexpensive and fast; one egg of an SPF hen produces 20-80 daily doses (at 6 mg/dose) within 3 weeks from the first injection (1 week after the first boost). We found a limited variability between individual immunized hens as determined by ELISA and Western blot analyses and a batch-to-batch consistency (Fig. 3D-G.). IgY is also easy to distribute; besides the known long-term stability of purified IgY [61], we also found excellent stability of the formulated material at 2-8°C for at least 6 months (maximum time point measured so far) and greater than 2 weeks when stored at room temperature. This is in contrast to vaccines, some of which require cold-chain storage at -80°C that complicates the logistics of global distribution and to resource-poor regions, in particular.

Another important advantage of IgY-based prophylaxis is the ease of local production, including in low- and middle-income countries. As hen immunization is a standard procedure around the world, IgY purification and formulation do not require expensive equipment and are simple to carry out. In a separate study, we determined that the production of anti-SARS-CoV-2 antibodies against the same immunogen using commercial hens and the resulting IgY had very similar activities to that of SPF hens, although the amount of IgY produced per egg was lower. In addition, both the immunized hens and their eggs are safe for humans, even for consumption as food, making the production of this prophylaxis easy to adopt in non-specialized facilities in low-income countries. Therefore, anti-SARS-CoV-2 IgY can be readily made available worldwide as an additional means of reducing SARS-CoV-2 infection. Each day, one immunized hen can produce the daily dose required for prophylaxis of a family. In addition, by reducing viral mobility and anchoring the virus to the nasal mucus, transmission of the virus from infected to healthy individuals may be reduced.

Conclusion

The current COVID-19 pandemic illustrates the need for prophylactics that can be produced rapidly at low cost, are technically accessible anywhere in the world, and complement traditional vaccine development. The safety and benefit of IgY and the ease to produce it at low cost are well described for animal farms. In contrast, the clinical adaptation of IgY for human use has been slow, likely hampered by a lack of intellectual property that has hindered commercial development by industry. For that reason, we undertook the effort of establishing the ability of anti-SARS-CoV-2 IgY to neutralize variants of concern and the initial safety of the IgY preparation using industry GLP and GMP standards. We suggest that until vaccination that is highly effective against prevalent variants becomes available worldwide or herd immunity is achieved, intranasal delivery of anti-SARS-CoV-2 IgY may provide passive immunization, including for use as an add-on to personal protective equipment and other preventive measures for the general population. This IgY may also provide short-term protection in addition to vaccines in less well-ventilated environments, including in trains, airplanes, lecture halls, etc. We also suggest that this approach has the potential to provide a means to curb new threats of epidemics by airborne infectious agents; by providing the relevant immunogen for hen immunization at the geographical site where the threat was detected, an effective passive immunity can be initiated locally to stop the spread of the airborne infectious agent before it becomes an epidemic. We hope that this study will trigger further work to evaluate the safety and efficacy of anti-SARS-CoV-2 IgY in those at risk of SARS-CoV-2 infection.

Acknowledgments

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

We thank our many SPARK at Stanford advisors for their support, both financially and through their invaluable advice. We wish to thank Miao Wen, Nina A. Carlos, Lawrence Huang, Cuong Tran, Stephanie Armstrong, and Daniel Calarese of Sutro Biopharma for their help in the

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

production of the cell-free expressed RBD, Roxanne Lopardo at Avian Vaccine Services, Charles River Laboratories for her work in IgY testing, and David Goodkin for helpful advice and critical review. We also thank the study staff at Linear Clinical Research Ltd and Resolutum Global for their outstanding conduct and analysis of the phase 1 clinical study and Yael Rosenberg-Hasson, Tyson H Holmes, Prof. Mark Davis, and other members of the Immunoassay Team at the Human Immune Monitoring Center (Stanford University) for cytokine analyses and statistical consultation. Linda MacKeen provided invaluable editing support. References 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. [Cited January 4, 2022]. Available from: https://covid19.who.int/ 2. University of Oxford. Vaccination by location. [Cited January 4, 2022]. Available from: https://ourworldindata.org/covid-vaccinations?country=OWID WRL 3. Irwin A. What it will take to vaccinate the world against COVID-19. Nature. 2021; 592: 176-178. 4. Lopman BA, Shioda K, Nguyen Q, Beckett SJ, Siegler AJ, Sullivan PS, et al. A framework for monitoring population immunity to SARS-CoV-2. Ann Epidemiol. 2021; 63: 75-78. 5. Koff WC, Schenkelberg T, Williams T, Baric RS, McDermott A, Cameron CM, et al. Development and deployment of COVID-19 vaccines for those most vulnerable. Sci Transl Med. 2021; 13: eabd1525. 6. Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics. Nat Biomed Eng. 2020; 4: 1128-1133. 7. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira IATM., et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021; 599: 114-119.

- 8. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced
- neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;
- 1123 184: 4220-4236.
- 9. National Institutes of Health, National Center for Advancing Translational Sciences.
- OpenData Portal. SARS-CoV-2 Variants & Therapeutics. [Cited January 4, 2022].
- Available from: https://opendata.ncats.nih.gov/variant/summary
- 10. Zhang Z, Wu S, Wu B, Yang Q, Chen A, Li Y, et al. SARS-CoV-2 Omicron strain exhibits
- potent capabilities for immune evasion and viral entrance. Sig Transduct Target Ther.
- 1129 2021; 6: 430.
- 11. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepada SK, Culap K, et al. Broadly
- neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature.
- December 23, 2021. https://doi.org/10.1038/d41586-021-03825-4
- 12. Liu L, Iketani S, Guo Y, Chan J F-W, Wang M, Liu L, et al. Striking Antibody Evasion
- Manifested by the Omicron Variant of SARS-CoV-2. Nature. December 23, 2021;
- https://doi.org/10.1038/d41586-021-03826-3
- 13. University of Oxford. SARS-CoV-2 variants in analyzed sequences (by country). [Cited
- January 4, 2022]. Available from: https://ourworldindata.org/grapher/covid-variants-
- 1138 area?country=~USA
- 14. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev
- 1140 Microbiol. 2021; 19: 141-154.
- 15. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function,
- and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181: 281-292.

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

16. Zhang Z, Wu S, Wu B, Yang Q, Chen A, Li Y, et al. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Sig Transduct Target Ther. 2021; 6: 430. 17. Murin CD, Wilson IA, Ward AB. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nat Microbiol. 2019; 4:734–747. 18. Weltzin R, Monath TP. Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev. 1999; 12: 383-393. 19. Cai Q, Hanson JA, Steiner AR, Tran C, Masikat MR, Chen R, et al. A simplified and robust protocol for immunoglobulin expression in Escherichia coli cell-free protein synthesis systems. Biotechnol Prog. 2015; 31: 823-831. 20. Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, et al. Microscale to manufacturing scale-up of cell-free cytokine production - a new approach for shortening protein production development timelines. Biotechnol Bioeng. 2011; 108:1570-1578. 21. SAS Institute Inc. 2015. SAS/IML® 14.1 User's Guide. Cary, NC: SAS Institute, Inc. 22. Chan J F-W, Zhang AJ, Yuan S, Poon V K-M, Chan C C-S, Lee A C-Y, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a Golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020; 71:2428-2446. 23. Bricker TL, Darling TL, Hassan AO, Harastani HH, Soung A, Jiang X, et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 2021; 20; 36:109400.

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

24. Neerukonda SN, Vassell R, Herrup R, Liu S, Wang T, Takeda K, et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS One. 2021; 16: e0248348. 25. Kollberg H, Carlander D, Olesen H, Wejåker PE, Johannesson M, Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol. 2003; 35:433-440. 26. Lee C-D, Sun H-C, Hu S-M, Chiu C-F, Homhuan A, Liang S-M, et al. An improved SUMO fusion protein system for effective production of native proteins. Protein Sci. 2008; 17: 1241-1248. 27. Pokhrel S, Kraemer BR, Lee L, Samardzic K, Mochly-Rosen D. Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants' spike protein-an in silico analysis. PLoS One. 2021; 16: e0251426. 28. Pokhrel S, Kraemer BR, Burkholz S, Mochly-Rosen D. Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies. Sci Rep. 2021; 11: 13120. 29. (no authors) COVID-19 Vaccine Comparison Chart. Med Lett Drug Ther. [Cited January 4, 2022]. Available from: https://secure.medicalletter.org/downloads/1621g_table.pdf 30. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum Lancet. 2021; S0140-6736:02844-0.

31. Chemical Computing Group. Molecular Operating Environment (MOE). Montreal, 1186 Canada. 2021. 1187 32. Centers for Disease Control and Prevention. Science Brief: Omicron (B.1.1.529) variant. 1188 [Cited January 4, 2022]. Available from: https://www.cdc.gov/coronavirus/2019-1189 ncov/science/science-briefs/scientific-brief-omicron-variant.html 1190 1191 33. Centers for Disease Control and Prevention. Potential Rapid Increase of Omicron Variant 1192 Infections in the United States. [Cited January 4, 2022]. Available from: 1193 https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical-modeling-1194 outbreak.html 34. Carlander D, Stålberg J, Larsson A. Chicken antibodies: a clinical chemistry perspective. 1195 Ups J Med Sci. 1999; 104:179-189. 1196 35. Lee L, Samardzic K, Wallach M, Frumkin LR, Mochly-Rosen D. Immunoglobulin Y for 1197 potential diagnostic and therapeutic applications in infectious diseases. Front Immunol. 1198 1199 2021;12:696003. 36. Artman C, Brumfield KD, Khanna S, Goepp J. Avian antibodies (IgY) targeting spike 1200 glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit 1201 1202 receptor binding and viral replication. PLoS One. 2021;16:e0252399. 1203 37. Shen H, Cai Y, Zhang H, Wu J, Ye L, Yang P, et al. Anti-SARS-CoV-2 IgY isolated from 1204 egg yolks of hens immunized with inactivated SARS-CoV-2 for immunoprophylaxis of 1205 COVID-19. Virol Sin. 2021; 36:1080-1082. 1206 38. Bao L, Zhang C, Lyu J, Yi P, Shen X, Tang B, et al. Egg yolk immunoglobulin (IgY)

targeting SARS-CoV-2 S1 as potential virus entry blocker. J Appl Microbiol. 2021 Oct

27:10.1111/jam.15340. doi: 10.1111/jam.15340.

1207

1208

39. Wei S, Duan S, Liu X, Wang H, Ding S, Chen Y, et al. Chicken egg yolk antibodies (IgYs) 1209 block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. Int 1210 Immunopharmacol. 2021;90:107172. 1211 40. Lu Y, Wang Y, Zhang Z, Huang J, Yao M, Huang G, et al. Generation of chicken IgY 1212 against SARS-COV-2 spike protein and epitope mapping. J Immunol Res. 1213 1214 2020;2020:9465398. 41. Lyu J, Bao L, Shen X, Yan C, Zhang C, Wei W, et al. The preparation of N-IgY targeting 1215 1216 SARS-CoV-2 and its immunomodulation to IFN-y production in vitro. Int 1217 Immunopharmacol. 2021;96:107797. 42. Marttin E, Schipper GM, Verhoef JC, Merkus WHM. Nasal mucociliary clearance as a 1218 factor in nasal drug delivery. Adv Drug Deliv Rev. 1998; 29: 13-38. 1219 43. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious 1220 1221 diseases. Clin Microbiol Rev. 2000; 13: 602-614. 44. Hemmingsson P, Hammarström L. Nasal administration of immunoglobulin as effective 1222 prophylaxis against infections in elite cross-country skiers. Scand J Infect Dis. 1993; 25: 1223 783-785. 1224 1225 45. Lindberg K, Berglund B. Effect of treatment with nasal IgA on the incidence of infectious 1226 disease in world-class canoeists. Int J Sports Med. 1996; 17: 235-238. 1227 46. Giraudi V, Riganti C, Torales MR, Sédola H, Gaddi E. Upper respiratory infections in 1228 children: Response to endonasal administration of IGA. Int J Pediatr Otorhinolaryngol.

1997; 39: 103-110.

1229

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

47. Heikkinen TA, Ruohola A, Ruuskanen O, Waris M, Uhari M, Hammarström L. Intranasally administered immunoglobulin for the prevention of rhinitis in children. Pediatr Infect Dis J. 1998; 17: 367-372. 48. Gleich GJ, Yunginger JW. Ragweed hay fever: treatment by local passive administration of IgG antibody. Clin Allergy. 1975; 5:79-87. 49. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH 3rd, et al. SARS-CoV-2 Reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020; 182: 429-446.e14. 50. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respiratory J. 2020; 55: 2000607. 51. Kovacs-Nolan J, Mine Y. Egg yolk antibodies for passive immunity. Ann Rev Food Sci Technol. 2012; 3: 163-182. 52. Kim Y-II, Kim D, Yu K-M, Seo HD, Lee S-A, Casel MAB, et al. Development of Spike receptor-binding domain nanoparticles as a vaccine candidate against SARS-CoV-2 infection in ferrets. mBio. 2021; 12: e00230-21. 53. Palit P, Chattopadhyay D, Thomas SS, Kundu A, Kim HS, Rezaeif N. Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19? Phytomedicine. 2021; 85: 153396. 54. Burton MJ, Clarkson JE, Goulao B, Glenny A-M, McBain AJ, Schilder AG, et al. Worthington, Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection. Cochrane Database Syst Rev. 2021; 9: CD013626.

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

55. Higgins TS, Wu AW, Illing EA, Sokoloski KJ, Weaver BA, Anthony BP, et al. Intranasal antiviral drug delivery and coronavirus disease 2019 (COVID-19): A state of the art review. Otolaryngol Head Neck Surg. 2021; 163:682-694. 56. Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021; 595: 718-723. 57. Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, et al. Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci Adv. 2021; 7: eabh0319. 58. Fu Y, Maruyama J, Singh A, Lim R, Ledesma A, Lee D, et al. Protective effects of sti-2020 antibody delivered post-infection by the intranasal or intravenous route in a Syrian Golden Hamster COVID-19 model. bioRxiv [Preprint]. Posted October 29, 2020, Cited January 4, 2022. Available from: https://www.biorxiv.org/content/10.1101/2020.10.28.359836v1 59. Watanabe Y, Berndsen ZT, Raghwani J, Seabright GE, Allen JD, Pybus OG, et al. Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nat Commun. 2020; 11: 2688. 60. Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, et al. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol. 2001; 75:12088-12097. 61. Schade R, Gutierrez Calzado E, Sarmiento R, Chacana PA, Porankiewicz-Asplund J, Terzolo HR. Chicken egg yolk antibodies (IgY-technology): a review of progress in

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

production and use in research and human and veterinary medicine. Altern Lab Anim. 2005; 33:129-154. **Supporting information captions** S1 Protocol. Phase 1 Clinical Trial Protocol. S1 CONSORT Checklist. S1 Table. Rat toxicity study protocol. S2 Table. Bioanalytical sample collection from the rat toxicity study. S3 Table. Cytokine sample collection for the rat toxicity study. S4 Table. Human tissue cross-reactivity; list of tissues examined. **S1 Figure.** Efficacy study in hamsters. Placebo control and IgY-treated Syrian hamsters were challenged with 4 x 10⁶ or 8 x 10⁵ PFU SARS-CoV-2; titer was determined in Vero E6 cells. However, the viral titers on Vero-hACE2-hTMPRSS2, which includes the essential protease to liberate the RBD from the S protein on the surface of the virus [24], was almost 100-fold higher at 4 x 10⁶ or 0.8 x 10⁶. Infectious virus titers were measured in the lungs 3 days post-infection by plaque assay. Each symbol is a single animal. One animal in the placebo group challenged with a low dose of the virus did not have any detectable virus in the lung homogenate. This was ruled an outlier based on the viral RNA levels in other assays. Viral RNA levels were assessed by RTqPCR in lung homogenates of nasal swabs using 2 different primer-probe sets. Each symbol is a single animal and the bars represent the geometric mean with geometric standard deviation. **S2 Figure. Serum cytokines from study participants.** Serum cytokines for human participants in the phase 1 study. Blood cytokine levels before treatment (D1 pre-dose), 2 hours after the first treatment (D1H2), 24 hours after 3-times daily intranasal (D2 pre-dose), and 2 hours after the

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

first dose on the second day (D2H2) of anti-SARS-CoV-2 RBD IgY (0, 2, 4 and 8 mg/dose). Data are adjusted for nonspecific binding and plate artifacts plus the effects of individual persons. Red indicates a statistical difference with a false discovery rate (FDR) significant pvalue (p < 0.05). **Funding** This project was supported by funds from SPARK at Stanford, SPARK GLOBAL, and grants from the Booz-Allen Foundation and ChEM-H (Stanford University). We are also grateful for the financial support from the Moonchu Foundation, the Human Immune Monitoring Center (HIMC) at Stanford University, and the generous monetary donations of many others. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. **Competing interests** None of the authors declare competing interests. Data and materials availability All data are available in the main text or Supporting Information. The study is registered at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04567810). **Disclaimer** Opinions, conclusions, interpretations, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army. The mention of trade names or commercial products does not constitute endorsement or recommendation for use by the Department of the Army or the Department of Defense.

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1337


Author contributions Conceptualization: Michael Wallach, Daria Mochly-Rosen, Lyn R. Frumkin Methodology: Lyn R. Frumkin, Michaela Lucas, Curtis L. Scribner, Nastassja Ortega-Heinly, Alice Yam, Trevor J Hallam, Alice Yam, Kristin Bedard, Courtney A. Cohen, John M. Dye, Brian McMillan, Adrianus C.M. Boon, Tom St. John **Investigation**: Michaela Lucas, Nastassja Ortega-Heinly, Gang Yin, Courtney A. Cohen, Catherine V. Badger, Shawn A. Abbasi, Traci L. Bricker, Astha Joshi, Suman Pokhrel, Benjamin R. Kraemer, Lucia Lee Visualization: Lucia Lee, Daria Mochly-Rosen Funding Acquisition: Daria Mochly-Rosen, Stephen Kargotich **Project Administration**: Mahima Agogiya, Rebecca Begley, Lucia Lee, Jayden Rogers **Supervision**: Jayden Rogers, John M. Dye, Brian McMillan, Trevor J Hallam, Adrianus C.M. Boon, Stephen Kargotich, Daria Mochly-Rosen Writing – original draft: Daria Mochly-Rosen, Lyn R. Frumkin **Writing – review -** all authors Writing – editing: Daria Mochly-Rosen, Lyn R. Frumkin, Benjamin R. Kraemer, Tom St. John

FIG 1



CONSORT 2010 Flow Diagram

Part I: Single-Ascending Dose (Cohorts A-C consecutively enrolled)



Part II: Multiple Dose (concurrent enrollment) **Enrollment** Assessed for eligibility (n= 24) Randomized (n= 24) Allocation Allocated to 6 mg daily anti-Allocated to 12 mg daily anti-Allocated to placebo (n=6) Allocated to 24 mg daily anti-SARS-CoV-2 IgY (n=6) SARS-CoV-2 IgY (n=6) SARS-CoV-2 IgY (n=6) ◆ Received allocated Received allocated Received allocated ◆ Received allocated intervention (n= 6) intervention (n= 6) intervention (n= 6) intervention (n= 6) Follow-Up Lost to follow-up (n=0) Lost to follow-up (n=0) Lost to follow-up (n=0) Lost to follow-up (n=0) Discontinued intervention Discontinued intervention Discontinued intervention Discontinued intervention (n=0)(n=0)(n=0)(n=1)*discontinued after 3 doses (Day 1) due to upper respiratory tract infection. **Analysis** Analyzed (n=6) Analyzed (n=6) Analyzed (n=6) Analyzed (n=6)







Fig 3


FIG 3








| TEST | FINDINGS |
|---------------|---|
| CLINICAL | No drug-related clinical observations. |
| OBSERVATIONS | |
| CLINICAL | No differences in hematology, coagulation, or |
| PATHOLOGY | clinical chemistry parameters. |
| FOOD | No notable differences in food consumption. |
| s CONSUMPTION | |
| BODY WEIGHT | No notable differences in mean body weights. |
| OPHTHALMIC | No drug-related ocular findings |
| NECROPSY | No drug-related macroscopic and microscopic |
| OBSERVATIONS | findings, including nasal histology. |





S1 Protocol



Protocol Number: CVR001

A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)

Investigational Drug: Anti-SARS-CoV-2 IgY

Sponsor: SPARK at Stanford

Sponsor Contact:
Daria Mochly-Rosen, PhD
Professor, Dept. of Chemical and Systems Biology
George D. Smith Professor of Translational Medicine
CCSR Room 3145a, 269 Campus Drive
Stanford University School of Medicine
Stanford, California 94305-5174
Tel: (650) 725-7720 (mobile)
E-mail: mochly@stanford.edu

Version 3.0, dated 29 September 2020

The information contained in this protocol is confidential and intended for the use of the study staff. The information in this document is the property of the sponsor and may not be disclosed unless federal or state law or regulations require such disclosure. Subject to the foregoing, this information may be disclosed only to those persons involved in the study who need to know, with the obligation not to further disseminate this information.

S1 CONSORT Checklist



CONSORT 2010 checklist of information to include when reporting a randomised trial*

| Section/Topic | Item No | Checklist item | Reported on page No |
|--------------------------|------------|---|---------------------|
| Title and abstract | | | |
| | 1a | Identification as a randomised trial in the title | 1 |
| | 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) | 3 |
| Introduction | | | |
| Background and | 2a | Scientific background and explanation of rationale | 4-7 |
| objectives | 2b | Specific objectives or hypotheses | 6-7 |
| Methods | | | |
| Trial design | 3a | Description of trial design (such as parallel, factorial) including allocation ratio | 11-18 |
| | 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | NA |
| Participants | 4a | Eligibility criteria for participants | 11 |
| | 4b | Settings and locations where the data were collected | 11 |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 11-18 |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | 11-18 |
| | 6b | Any changes to trial outcomes after the trial commenced, with reasons | NA |
| Sample size | 7a | How sample size was determined | 16 |
| • | 7b | When applicable, explanation of any interim analyses and stopping guidelines | 16-17 |
| Randomisation: | | | |
| Sequence | 8a | Method used to generate the random allocation sequence | 11-12 |
| generation | 8b | Type of randomisation; details of any restriction (such as blocking and block size) | 11-12 |
| Allocation | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), | 11-12 |
| concealment mechanism | | describing any steps taken to conceal the sequence until interventions were assigned | |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 11-12 |
| Blinding | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those | 11 |


CONSORT 2010 checklist

| | | assessing outcomes) and how | |
|---------------------|-----|---|---------------|
| | 11b | If relevant, description of the similarity of interventions | NA |
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes | 16 |
| | 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | NA |
| Results | | | |
| Participant flow (a | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and | 11 |
| diagram is strongly | | were analysed for the primary outcome | |
| recommended) | 13b | For each group, losses and exclusions after randomisation, together with reasons | 38 |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | 11 |
| | 14b | Why the trial ended or was stopped | NA |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | 26-27 |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was | 11-18 |
| | | by original assigned groups | |
| Outcomes and | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its | 27-29 |
| estimation | | precision (such as 95% confidence interval) | |
| | 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | 27-29 |
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 30 |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | 27-28 |
| Discussion | | | |
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 30 |
| Generalisability | 21 | Generalisability (external validity, applicability) of the trial findings | 30 |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 30-37 |
| Other information | | | |
| Registration | 23 | Registration number and name of trial registry | 11 |
| Protocol | 24 | Where the full trial protocol can be accessed, if available | S2 Supporting |
| | | | Information |
| Funding | 25 | Sources of funding and other support (such as supply of drugs), role of funders | 49 |


^{*}We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.


CONSORT 2010 checklist Page 2

S1 Fig



S2 Figure





S1 Table. The experimental protocol of rat toxicity study

| | | | | | No. of | Animals | |
|--------------|--------------------|-----------------------------|----------------------------------|--------------------------|---------|------------|---------|
| | | | | Main Study Toxicokinetic | | etic Study | |
| Group No. | Test Material | Dose Volume (µL dose) | Dose Concentration (mg/mL) | Males | Females | Males | Females |
| 1 | Control Article | 100 | 0 | 10 | 10 | 3 | 3 |
| 2 | IgY SARS-CoV-2 RBD | 100 | 20 | 10 | 10 | 6 | 6 |
| 3 | Control Article | 100 | 0 | 3ª | 3ª | - | - |
| 4 | IgY SARS-CoV-2 RBD | 100 | 20 | 3ª | 3ª | - | - |

^a = These animals were for cytokine analysis only.

S2 Table. Bioanalytical sample collection from the rat toxicity study

| | | (Time Post the first daily do | | | e) on Day 1 |
|-----------|----------|-------------------------------|--------|-------|-------------|
| Group No. | Subgroup | No. of Animals (M/F) | 15 min | 6ª hr | 24 hr |
| 1 | А | 3/3 | Х | - | Х |
| 2 | А | 3/3 | Х | - | Х |
| | В | 3/3 | - | Х | - |

| Method/Comments: | Venipuncture of the jugular vein (under isoflurane anesthesia). The tail vein may be used if blood cannot be obtained via the jugular vein. |
|-----------------------|---|
| Target Volume (mL): | 0.3 |
| Anticoagulant: | K₂EDTA |
| Special requirements: | Tubes will be chilled after blood collection. |
| Processing: | Plasma |

X = Sample to be collected; M = Male; F = Female; - = Not applicable

^a Sample to be collected before the second daily dose.

S3 Table. Cytokine sample collection for the rat toxicity study

| | | (Time Post the first daily dose) on Day 28 | | |
|-----------|----------------------|--|------|-------|
| Group No. | No. of Animals (M/F) | 0ª hr | 4 hr | 24 hr |
| 3 | 3/3 | Х | Х | Х |
| 4 | 3/3 | Х | Х | Х |

| Method/Comments: | Venipuncture of the jugular vein (under isoflurane anesthesia). The tail vein may be used if blood cannot be obtained via the jugular vein. |
|-----------------------|---|
| Target Volume (mL): | 0.3 |
| Anticoagulant: | K₂EDTA |
| Special requirements: | Tubes will be chilled on wet ice after blood collection. |
| Processing: | Plasma |

X = Sample to be collected; M = Male; F = Female; - = Not applicable

^a Sample to be collected before dosing.

S4 Table. Human tissue cross-reactivity; list of tissues examined.

Binding of anti-SARS-CoV-2 RBD IgY was determined using the following normal human tissue from 3 separate donors.

| Adrenal | Liver | Spinal Cord | |
|--|------------------|----------------------------|--|
| Bladder (urinary) | Lung | Spleen | |
| Blood Cells ^a | Lymph Node | Striated Muscle (skeletal) | |
| Blood Vessels (endothelium) b | Ovary | Testis | |
| Bone Marrow | Nasal Mucosa | Thymus | |
| Brain - cerebellum | Pancreas | Thyroid | |
| Brain - cerebral cortex | Parathyroid | Tongue | |
| Breast (mammary gland) | Peripheral Nerve | Tonsil | |
| Eye | Pituitary | Trachea | |
| Fallopian Tube (oviduct) | Placenta | Ureter | |
| Gastrointestinal (GI) Tract ^c | Prostate | Uterus - cervix | |
| Heart | Salivary Gland | Uterus- endometrium | |
| Kidney (glomerulus, tubule) | Skin | | |

^a Evaluated from peripheral blood smears.

^b Evaluated from all tissues where present.

^c Included esophagus, large intestine/colon, small intestine, and stomach (including underlying smooth muscle).